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Abstract
In this thesis, a mathematical model describing the interaction between HIV and TB
in the presence of TB superinfection is presented. The model takes into account two
strains of Mycobacterium tuberculosis (MTB), where one strain is drug-sensitive and the
other is resistant to at least one of the first-line anti-tuberculosis drugs. The impact
of TB superinfection on the incidence and prevalence of TB in HIV-negative and HIV-
TB coinfected individuals is evaluated. Various control measures such as condom use,
antiretroviral therapy, isoniazid preventive therapy and increased TB detection are studied
using this model. Numerical results show that TB superinfection increases the prevalence
and incidence of TB and its impact is more in HIV-negative than HIV-TB coinfected
individuals. The results also show that TB superinfection promotes strain coexistence and
increases the associated HIV mortality. Increased condom use was found to have a high
positive impact towards the control of the two epidemics. Antiretroviral therapy decreases
the TB notification rate and its impact on HIV prevalence increases with the coverage and
efficacy. Isoniazid preventive therapy has a clear effect on the TB prevalence. Finally,
increased TB detection was found to have a less impact on the TB incidence in HIV-TB
coinfected individuals.
Opsomming
In hierdie verhandeling word ´n wiskundige model vir die interaksie tussen MIV en TB,
in ´n situasie met TB superinfeksie voorgeleˆ. Die model neem twee variante van TB in
ag. Een van die variante is sensitief vir MTB behandeling, terwyl die ander weerstandig is
vir ten minste een van die eerste-linie TB behandenings. Die impak van TB superinfeksie
op die insidensie and prevalensie van TB in MIV negatiewe en MIV-TB ko-ge˜ınfekteerde
individu word ondersoek. Veskeie beheer maatreels soos kondoom gebruik, anti-retrovirale
behandeling (vir MIV) en isonazid voorkomende behandeling en verhoodge TB deteksie
(vir TB) word ondersoek. Numeriese resultate wys TB superinfeksie verhoog die prevalense
en insidensie van TB en dat dit ´n groter bydrae maak by MIV negatief as by MIV-TB
ko-geinfekteerde individu. Die resultate wys veder TB superinfeksie promofeer variant ko-
habitasie en verhoog MIV verwante mortalitieit. Verhoogde kondoom gebruik is gevind om
´n positiewe bydrae te maak tot die beheer van beide epidemies. Anti-retrovirale terapie
verlaag die TB aanmeldings koers en die impak van ART verhoog saam met ´n verhoging in
die dekking en effektiwiteit daarvan. Voorkomende behandeling het ´n beduidende impak
op TB prevalensie. Ons vind dat TB deteksie ´n beperkte impak maak op TB insidensie
by MIV-TB ko-geinfekteerde individu.
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Chapter 1
Introduction
1.1 Epidemiology of tuberculosis infection
Tuberculosis (TB) is an airborne disease that is caused by the bacteria Mycobacterium
tuberculosis (MTB) which normally attacks the lungs (pulmonary tuberculosis). In an
uncommon situation, MTB also attacks the other parts of the body such as the nervous
system, bones, joints, lymph nodes, skin and the digestive system (extrapulmomary tuber-
culosis). It is only active pulmonary tuberculosis that is infectious. Coughing up blood,
loss of weight, breathlessness, fever and fatigue are some of the symptoms that can be
witnessed in an individual infected with tuberculosis. Tuberculosis is one of the leading
causes of mortality, second to humman immunodeficiency virus (HIV) [21].
An uninfected individual gets MTB from another individual who is actively infected with
pulmonary tuberculosis through contact, especially when an infected individual coughs,
sneezes, laughs, spits or talks. Once an individual gets MTB one can progress to active
disease within the first five years or can remain latently infected with TB throughout
his/her life time. This is referred to as primary infection. Only 5-10% of the individuals
can progress to active disease through primary infection. If an individual progress to active
disease within the first five years, then this is called fast progression. Latently infected
individuals can live with the bacteria for years and some can even die without developing
active tuberculosis. Individuals with the latent infection are non-infectious and do not show
any symptoms of tuberculosis since they will not be clinically ill [54]. Susceptibility to MTB
1
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infection varies from one individual to the other. Those that are at a high risk of getting
tuberculosis include: people with HIV, people in close contact with tuberculosis patients,
people who are malnourished, health care workers, prisoners, alcoholics, intravenous drug
users and the homeless [19].
Individuals latently infected with tuberculosis can only progress to active disease in two
ways.
 Through reactivation of the latent infection, initially obtained from the primary
infection [14, 54]. This is known as endogenous reactivation.
 Through reinfection where by an individual acquires a new infection from another
individual who is actively infected with pulmonary tuberculosis [14, 54]. This is
known as exogenous reinfection.
These two situations are categorised as post-primary infections. Also categorised under
post-primary infection is superinfection. A detailed discussion on superinfection is given
in subsection 1.1.3.
It is known that a third of the world’s population is infected with Mycobacterium tubercu-
losis [33, 39]. New cases of active TB (about 9 million) arise every year in the world with
the highest percentage contribution being from the developing countries (mostly Asia and
sub-Saharan Africa). About 1.6 million people died of TB in the world in 2005 and out of
these 195,000 (12%) were HIV-infected patients [20].
The recent report released by WHO, indicates that there were 9.2 million new TB cases
in 2006, including 700,000 (8%) cases among people living with HIV and 500,000 (5.4%)
cases of multidrug resistant TB. 1.7 million people died of TB and out of these 200,000
(11.8%) were HIV-positive. Asia and sub-Saharan Africa were the most hit regions having
83% of the new tuberculosis infections in 2006 [38].
The HIV burden has greatly increased the prevalence and infection of tuberculosis in sub-
Saharan Africa where the HIV epidemic is high [54]. The emergence of drug-resistant
and multidrug-resistant strains have also contributed significantly to the TB epidemic.
From 2000 to 2007, on average 56.3% of the TB cases reported were resistant to least one
anti-tuberculosis drug and 22.3% were multidrug-resistant [53].
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1.1.1 Tuberculosis control
The vaccine bacille Calmette-Gue´rin (BCG) is used in most countries. Young children are
vaccinated with BCG to impart some degree of protection against tuberculosis. However,
this protection is thought to be declining over time due to interactions between the vaccine
and environmental mycobacteria mostly in tropical regions [14, 31].
Control of tuberculosis involves treating active disease, stopping secondary infections and
preventing primary infections. In recognition to these facts, the World Health Organisation
(WHO) instituted a strategy called directly observed treatment, short-course (DOTS),
which is based on early diagnosis and directly observed treatment of active cases [45].
Currently, latent infections are treated with isoniazid (INH) which is administered for six
to twelve months. Alternatively, rifampicin could as well be used instead of isoniazid for
four months. Active tuberculosis is treated by a combination of isoniazid, rifampicin for
six months and then supplemented by pyrazinamide and ethambutol for two months to
reduce the possibility of emergence of drug-resistance. If the patient is co-operative and is
able to take regularly and finish the regimen, then the first combination is enough to cure
tuberculosis. However, if mono-resistance to rifampicin is detected, then the patient should
continue with isoniazid, pyrazinamide or ethambutol for 18 months. On the other hand,
the patient should continue with rifampicin, pyrazinamide or ethambutol for 12 months if
mono-resistance to isoniazid is detected [21].
The initiation of isoniazid preventive therapy (IPT) for treating latent tuberculosis re-
mains unclear. In poor countries where the prevalence of active tuberculosis is high and
the resources for ruling it out are limited, initiating IPT still remains a big problem. De-
velopment of drug-resistance is another concern that limits the implementation of IPT
[17].
1.1.2 Multidrug-resistant and extensively drug-resistant tuber-
culosis
Multidrug-resistant tuberculosis (MDR TB) is defined as one that is resistant to at least
isoniazid and rifampicin, the two best first-line anti-tuberculosis drugs. Extensively drug-
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resistant tuberculosis (XDR TB) is one that is resistant to isoniazid, rifampicin, any flu-
oroquinolone and at least 1 of 3 injectable second-line drugs capreomycin, kanamycin,
amikacin [9, 19, 44]. These two types of tuberculosis are common in individuals who;
 do not complete or take regularly their medicine as prescribed by physicians,
 get a relapse either after treatment or self-cure,
 come into contact with individuals that have drug-resistant tuberculosis [9, 19].
Drug resistance to tuberculosis can also arise due to poorly managed care and control of
the disease, poor prescribing practices and low drug quality. In a survey that was done
by Centers for Disease Control and Prevention (CDC) and World health Organisation
(WHO) to asses the worldwide frequency and distribution of MDR and XDR TB from
2000 to 2004, they reported that 20% of the TB cases were resistant to at least one of
the first-line anti-tuberculosis drugs and 2% resistant to second-line drugs [18]. People
with HIV are at a high risk of getting XDR-TB and MDR-TB. In 2006, over 200 cases of
MDR-TB were identified in the province of KwaZulu Natal in South Africa [35, 44]. MDR
TB treatment requires the use of second-line drugs that are less effective, more toxic and
expensive than first-line anti-tuberculosis drugs [18].
1.1.3 Tuberculosis superinfection
Superinfection refers to the multiple infection of a host with different strains of the same
parasite. These infections can take place at the same time or at a later point in time.
[7, 41, 26, 39]. Martcheva et al. [28] defined superinfection as the concurrent or subsequent
multiple infection of a host with the same parasite, may it be with identical or different
strains. In this thesis, we take superinfection in the same way it was considered in [7, 26, 39].
In some cases superinfection results in strain replacement whereby the more fit strain
replaces the less fit strain, and in other cases an individual can remain infected with two
strains (mixed infection). It has been postulated that superinfection shortens the latency
period of some bacterial diseases such as hepatitis A, speeds up the progression of HIV to
AIDS and plays a big role in activating the passive carriers of tuberculosis [26, 28].
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Evidence for superinfection in tuberculosis has already been reported [16, 29, 42]. Multiple
infections with different strains of M. tuberculosis may occur in areas where the prevalence
of active TB is high. This could possibly mean that superinfection is most likely to be
common in crowded areas. There are suggestions that superinfection may affect the diag-
nosis of drug-resistance most especially if a patient is infected with both drug-sensitive and
drug-resistant strains [29, 52]. This may be of much concern to physicians and clinicians
since it impacts control programmes and management of tuberculosis in general.
Because individuals who are infected with resistant strains stay longer in the infectious
state due to either improper regimen, late identification of the resistance phenotype, or
lower efficacy of treatment [30, 39], superinfection may lead to increased mortality. If the
treatment efficacy of an individual infected with only one resistant strain is low, then the
treatment efficacy for an individual infected with both resistant and sensitive strains could
be much lower.
1.2 Epidemiology of HIV infection
HIV is a human immunodeficiency virus that causes acquired immunodeficiency syndrome
(AIDS) and which has claimed the lives of many people in the world. The different modes of
HIV transmission include horizontal transmission (from one adult to another adult through
heterosexual or homosexual contact), vertical transmission (from an infected mother to
her unborn child) and transmission from one individual to another through either blood
transfusion or needle-sharing. Out of the three modes of HIV transmission, heterosexual is
the major mode of transmission contributing about 90% of the HIV infections in Africa [56].
HIV infection is associated with a progressive decrease of the CD4+ T cell count and an
increase in viral load. There are four stages of HIV infection which are based on the patients
CD4+ T cell count and these include: primary HIV infection, clinically asymptomatic stage,
symptomatic HIV infection and progression from HIV to AIDS. Progression to AIDS is
associated with an increased likelihood of opportunistic infections and other clinical events
associated with HIV, including wasting and death [37]. It normally takes an average of
10-15 years for an infected individual to progress to the AIDS stage in developed countries
and might be less in developing countries.
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By the end of 2007, it was estimated that 33.3 million people were living with HIV and out
of these 30.8 million were adults, 15.4 million were women and 2.5 million were children
under 15 years. Also 2.5 million people were newly infected with HIV and 2.1 million AIDS
death occurred in the same year. 76% of these deaths were in sub-Saharan Africa [50].
1.2.1 HIV control
The most plausible HIV control measures involve prevention of the infection. These preven-
tive strategies include condom use, abstinence, faithfulness and male circumcision. Condom
use and male circumcision were shown to have a big impact on HIV with male circumci-
sion alone reducing HIV transmission rate by 37% [5, 56]. Treatment of HIV consists of a
combination of antiretroviral therapies (ARV). These therapies are based on three or more
anti-HIV medications that typically combine a protease inhibitor (PI), or a non-nucleoside
reverse transcriptase inhibitor (nnRTI), with at least two nucleoside reverse transcriptase
inhibitors (nRTI). These drugs block the replication of the virus and thus increases the
survival time of HIV-infected individuals, but do not lead to viral eradication within indi-
viduals and hence do not cure [1, 23]. The effects of ART on HIV largely depends on the
stage of infection at which treatment is initiated, levels of coverage, the scale and stage
of HIV epidemic that the community is experiencing. ART has been shown to have a big
impact on HIV if the coverage is high [23, 34, 36].
1.3 Coinfection of HIV and TB
Coinfection refers to the simultaneous infection of a single host by two or more virus or
bacteria particles. So, an individual coinfection with TB and HIV carries both the MTB
bacteria and the HIV virus. The number of MTB infections is believed to have increased
in the last decade due to the coinfection of HIV and TB. These infections are thought
to be due to the development of tuberculosis among TB infected individuals that are
infected with HIV. On the other hand, treatment of tuberculosis has been hindered by the
emergence of HIV [15, 35, 43, 48]. Once an individual gets infected with HIV, the immune
system weakens due to the infection and thus susceptibility to opportunistic infections such
as tuberculosis increases [43]. Tuberculosis is the most common opportunistic infection in
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patients starting antiretroviral treatment (ART) worldwide [17, 35]. An individual who is
infected with HIV is at a high risk of latent MTB reactivation and can rapidly progress to
active TB soon after infection or reinfection with TB [15, 48]. Individuals infected with
MTB only have a life time risk of developing active TB that ranges between 10% to 20%,
but individuals coinfected with MTB and HIV have an annual risk of developing active
TB of 10% or more [15, 48]. Most individuals coinfected with MTB and HIV die due
to tuberculosis and yet tuberculosis is curable. The most worrying thing is that patients
with tuberculosis who are HIV-positive are susceptible to dying from other opportunistic
infections during their treatment period [15].
Little research has been done to understand the epidemiology of tuberculosis in children,
yet tuberculosis is a common cause of acute pneumonia in HIV-infected children. The
BCG vaccination which is widely used in most countries is associated with high mortality
in children who are on HIV treatment [17].
1.4 Motivation and overview
Tuberculosis and HIV are the major causes of mortality in the world. Tuberculosis is
one of the most common opportunistic infection in people with HIV, and HIV is also
known to have increased the burden of tuberculosis mostly in sub-Saharan Africa. A
number of mathematical models have been developed to describe the dynamics of one-
strain tuberculosis [2, 31, 32], two-strain tuberculosis [7, 39, 47, 55] and multi-drug resistant
tuberculosis [49]. Models looking at the joint epidemics of TB and HIV [13, 15, 34, 36,
43, 48] have also been presented. The question which has not been tackled so far is the
effect of superinfection on the incidence and prevalence of TB in individuals with and/or
without HIV. Evidence for mixed-infections (a situation where an individual is infected
with more than one strain) in tuberculosis and TB-HIV infected individuals has already
been reported [16, 29]. We are thus concerned about knowing the effects of superinfection
on the prevalence and incidence of tuberculosis.
Having given a general introduction and motivation of this work, the rest of this thesis is
structured as follows.
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In chapter 2, we give a review of mathematical models that have been developed to either
describe the dynamics of TB or HIV infection or HIV-TB coinfection.
In chapter 3, a simple mathematical model that describes the dynamics of tuberculosis in
the presence of two strains (drug-sensitive and drug-resistant strains) is developed. The
model incorporates in the aspect of superinfection. Mathematical analysis and simulations
of the model are given.
In chapter 4, we give an extention of the model described in chapter 3 to include HIV.
The mathematical analysis of the HIV-only model is given and simulations of the HIV-TB
coinfection model are given. A study on TB and HIV control measures is also done.
In chapter 5, we give a detailed conclusion on our findings.
Chapter 2
Literature review
Many researchers have developed and analysed mathematical models that endeavour to
explain the dynamics of TB infection and HIV-TB coinfection. These models vary in
terms of the number and variables representing compartments and the parameters used.
A few of these models have been fitted with data collected from epidemiological studies.
The data is however scarce and sometimes unavailable. We present a literature review
of some of the compartmental models that have been developed to explain the dynamics
of either TB or HIV infection or HIV-TB coinfection. We take note of the assumptions
made, the number of compartments used, the states of HIV and TB considered, the way
the parameters were estimated, the model analysis and interpretation and the data used
(if the model is fitted to data). We classify the models in different categories. We begin by
considering models with a single strain of TB. This is followed by models with two strains
of TB. We also revisit models on HIV infection dynamics before we conclude by looking
at the HIV-TB coinfection models.
2.1 Models on one strain of TB
In this section we give an overview of the models developed to describe the dynamics of
tuberculosis by looking at only one strain of MTB. This strain could either be a drug-
sensitive or drug-resistant or multi-drug resistant strain.
Ssematimba et al. [2], developed a model to investigate the effect of population density on
9
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the dynamics of tuberculosis in Uganda. The model used the TB transmission dynamics
earlier described in [4]. They established restrictions on the size of the area occupied by
individuals that would be needed in order to evaluate TB. They assumed homogeneous
mixing in the population, that is, uninfected individuals have equal chances of getting tu-
berculosis once they come into contact with an infectious individual. Their model consists
of four compartments; susceptible, latently infected, infectious and recovered or treated
individuals. They assumed that immigrants and new borns are uninfected with tuberculo-
sis. They did not consider exogenous reinfection. Mathematical analysis of the model was
done. Simulations were run and numerical results comparing the size of the area, recruit-
ment rate and the different epidemiological classes were obtained. Parameter values were
estimated from the literature. Their model suggested that overcrowding and unsanitary
conditions play a major role in explaining the observed trends of tuberculosis in Uganda
and the world in general.
Gomes et al. [31], developed a mathematical model to evaluate the impact of vaccina-
tion on human tuberculosis. The model consists of four compartments; susceptible, latent,
infectious and recovered or cured. They assumed individuals get infected with M. tubercu-
losis at a rate that is proportional to the density of infectious individuals. They introduced
bacille Calmette-Gue´rin (BCG) vaccination which was assumed to reduce the risk of M.
tuberculosis infection. They obtained a reinfection threshold, above which reinfection dom-
inates the transmission dynamics of tuberculosis. Their model was also used to evaluate the
efficacy of vaccination on the partial protection induced by the immune response against
reinfection. Parameter values were estimated from the literature. Simulations were run
for 400 years. The model suggested that vaccination does not improve on the protection
against reinfection.
In 2000, Dye and Williams [8], used a system of ten ordinary differential equations derived
from ten compartments to study the criteria for the treatment of multi-drug resistant
tuberculosis (MDR-TB) in adults over 15 years of age. The model contained eight states
of tuberculosis which include: susceptible, latent (slow breakdown to disease), latent (fast
breakdown to disease), infectious, non-infectious, treatment failure, self-cure and cure (by
treatment). Parameter values were estimated from the literature. Simulations were run
and numerical results based on the detection and cure rates obtained. In order to prevent
MDR-TB, they estimated that approximately 70% of infectious MDR-TB cases need to
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be detected and treated with a cure rate of 80% each year. They further suggested that
second-line drugs could be essential in increasing the cure rates of MDR-TB, although
these drugs are few, costly and sometimes toxic.
2.2 Models on two strains of TB
This section gives an overview of the models in the literature which describe the transmis-
sion dynamics of tuberculosis involving two-strains.
Rodrigues et al. [39], developed a TB transmission model which is an extention of the one
proposed by Gomes et al. [31]. The model included two strains with different sensitivities
to antibiotics (that is, one strain is drug-sensitive an the other is drug-resistant). The
model consists of five compartments looking at the host population divided into differ-
ent categories that is, susceptible, latently infected with a drug-sensitive strain, latently
infected with a drug-resistant strain, actively infected with a drug-sensitive strain and ac-
tively infected with a drug-resistant strain. They assumed that resistant strains can emerge
when individuals are infected with a resistant strain or as a result of treatment failure with
the former and the latter being termed primary resistance and acquired resistance respec-
tively. They also assumed that when an individual is infected with both resistant and
sensitive strains, then one will progress to tuberculosis of the resistant strain only. They
considered the same reactivation rate for both sensitive and resistant strains. They further
assumed that the period of infectiousness of a resistant TB case is on average two months
longer than that of a sensitive case. Stability and numerical analysis of the model were
done. An extension to mixed infections that considered progression to active TB of either
drug-sensitive or drug-resistant strain after superinfection was also given. They concluded
that primary resistance plays a significant role as far as infection with resistant strains is
concerned.
Castillo-Chavez et al. [7], developed two models to describe the transmission of TB. The
first model (one-strain TB model) consists of four compartments ie. susceptible, latent (in-
fected but not infectious), infectious and treated individuals. The second model (two-strain
TB model) is an extension of the first model. Two compartments ie latent and infectious
representing the developmental stages of the resistant strain were added. They ignored
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the treatment of the resistant strain by stating that its hard to be treated. They did not
consider fast progression after primary infection and exogenous reinfection of latent indi-
viduals. They also assumed that superinfection is only by resistant strains. Mathematical
and numerical analysis of the two models were done. They concluded that mixing plays a
key role in tuberculosis transmission.
Cohen and Murray [49], developed a model to describe the transmission dynamics of
multidrug-resistant (MDR) tuberculosis by giving special attention to the heterogeneity
of fitness of MDR strains and competition during an epidemic. The model consists of
nineteen ordinary differential equations. They assumed that MTB infection rate varies
according to the prevalence of people with active tuberculosis. They considered three dif-
ferent strains of tuberculosis; drug-sensitive TB, unfit MDR-TB and fit MDR-TB. They
also considered seven states of TB; susceptible, latent infection with slow progression,
latent infection with fast progression, undetected infectious TB, detected infectious TB,
infectious TB failed therapy and cured TB. Their parameter values were estimated from
the literature. They used their model to evaluate the implementation of directly observed
treatment, short-course (DOTS) treatment for both drug-sensitive and MDR-TB. Simula-
tions were run to evaluate the impact of DOTS 30 years after its initiation. Their model
suggested that fit MDR strains outcompete both the drug-sensitive and unfit MDR-TB
even in the presence of a well-functioning control programme.
2.3 Models for HIV
This section gives a review of the HIV infection models that have been formulated. We
give attention to the types of HIV transmission considered, control measures taken into
account and the way the parameters were estimated.
Kgosimore and Lungu [27] developed a model that describes the dynamics of HIV infec-
tion of both juveniles who were assumed to be infected through vertical transmission and
HIV/AIDS-infected adults. The model caters for treatment of both groups of people, first
in the absence of vertical transmission and then in the presence of vertical transmission.
The model consists of four sub-populations, susceptible, untreated infected, treated in-
fected and AIDS. People in the AIDS class were assumed to be sexually inactive and thus
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their sexual activity and infectivity was considered negligible. The reproduction numbers
of the model in the absence and presence of vertical transmission were calculated. They
obtained a critical threshold parameter (R∗v), below which treated juveniles can reach adult-
hood without causing an epidemic. Numerical simulations of the model were presented,
illustrating the results of five countries in sub-Saharan Africa which included Botswana,
Senegal, Swaziland, Uganda and Zambia. The model suggested that a significant propor-
tion of infected juveniles on treatment can reach adulthood without causing an epidemic.
Mukandavire et al. [56] developed a sex structured model to assess the effect of male
circumcision and condom use as control measures for HIV/AIDS. The model consists of
eight compartments, three for female populations and five for male populations. The
female and male populations were each partitioned into three sub-populations; susceptible,
infective and AIDS. The male susceptibles and infectives were further categorised into
two groups representing the uncircumcised and circumcised populations. Males in the
AIDS group were assumed to be sexually inactive and thus were taken to be in the same
category of uncircumcised population. The model also catered for emigration except for the
individuals in the AIDS class. The model’s numerical simulations were done to asses the
the effects of male circumcision and condom use in the absence of HIV/AIDS treatment.
The model suggested that male circumcision has a potential of reducing the transmission of
HIV/AIDS. They concluded that more effective results can be obtained if male circumcision
is combined with condom use.
Gross et al. [24] developed a model to describe the dynamics of HIV-1 in the presence of
superinfection and viral diversity. The model population was divided into two groups, low
and high risk groups based on the level of sexual activity. The model took into account
two subtypes of HIV-1 which were denoted by virus 1 and 2, and a recombinant of the
two viruses denote by virus 3. Susceptible individuals were assumed to be infected by
any combination of viruses given by set I, where I={1, 2, 3, 13, 23, 12, 123}. Infectious
individuals were also assumed to transmit any of the viruses given in set I. Newly infected
individuals were assumed to be susceptible to superinfection by other viral combinations
for a short period of time. Simulations were run for a period of 50 years after introducing
HIV-1 by limiting susceptibility to superinfection to an average of 30 days. It was found
that 20% of HIV-1 infections were recombinant and 4% were multiple infections after 25
years of the epidemic. They concluded that HIV-1 superinfection restricted to early HIV-1
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infection could result to high fractions of recombinant virus infections in a population.
2.4 Models for TB-HIV coinfection
This section gives an overview of the models developed to describe the dynamics of HIV-TB
coinfection.
Bacae˝r et al. [34], looked at a simple mathematical model that describes the interaction
between HIV and TB epidemics. Their model consists of six compartments with three
states of TB (susceptible, latent TB and active TB) and two states of HIV (HIV-negative
and HIV-positive). They considered one strain of TB in their model which was based on
research carried out in a South African township. Their model was fitted to data from
the township. They estimated some of the model parameters based on the collected data.
The model was used to evaluate some of the control measures which included condom use,
isoniazid preventive therapy, antiretroviral therapy (ART) and increased TB detection
rate. The model suggested that ART has a small impact on the incidence of HIV, though
it was found to reduce the TB notification rate. Increased condom use, TB detection and
preventive therapy were found to have a positive effect on the joint epidemics.
Currie et al. [12], developed a compartmental difference equation model based on TB
and HIV epidemics to compare the effectiveness of TB chemotherapy with highly active
antiretroviral therapy (HAART), treatment of latent TB infection (TLTI) and reduction of
HIV transmission. The model consists of three stages of HIV (HIV-negative, early stages
of HIV and late stages of HIV which is after four years of infection). HIV prevalence was
defined by a double logistic equation. One type of M. tuberculosis infection was considered
with six states (susceptible, latent, infectious TB, non-infectious TB, failed treatment and
receiving IPT). Their model was fitted to data from Kenya, Uganda and South Africa using
a Bayesian methodology. They used the data to obtain the numerical values of some of the
parameters. In addition to HAART and IPT, they also evaluated other control measures
such as condom use, increased TB detection and better TB cure. Simulations were run for
20 years from the year 2000 to 2020. The model showed that finding and curing active TB
and HAART are the most effective control measures for HIV and TB. TLTI and condom
use are relatively ineffective over a short period of time. They concluded that active TB
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treatment should be strongly emphasised.
Guwatudde et al. [13], developed a model to address the effect of preventive therapy (PT)
on tuberculosis in HIV infected individuals in sub-Saharan Africa. The model consists of
eleven compartments; five for HIV negative individuals, five for HIV positive individuals
and one for HIV positives who are latently infected with tuberculosis that are on PT.
They considered five states of tuberculosis; vaccinated, susceptible, latently infected, active
infectious TB and active non-infectious TB. BCG vaccination was considered to reduce on
the risk of getting infected with TB. They ignored exogenous reinfection of TB. They
assumed that individuals get infected with HIV at a constant rate. Their parameters
were estimated from the literature. Simulations were run for a period of 20 years. They
concluded that the impact of PT on TB in the population is likely to be small.
Cohen et al. [48], developed a mathematical model to evaluate the impact of isoniazid
preventive therapy (IPT) on TB-HIV coinfected individuals in sub-Saharan Africa. The
model consists of forty-five ordinary differential equations. It took into account two states
of HIV infection (HIV-negative and HIV-positive), and twenty-two states of TB infection.
Four stages of TB were considered (susceptible, latent, active and recovered), three types
of M. tuberculosis infection were considered (drug-sensitive, fit drug-resistant and unfit
drug-resistant TB). They assumed that some of the individuals with a latent infection
progress rapidly and others slowly to active TB. They also considered three types of active
TB, extra-pulmonary, detected pulmonary and undetected pulmonary TB. Apart from TB
treatment, the model also catered for the treatment of individuals who are HIV-positive.
It was assumed that an individual can be latently infected with a maximum of two strains.
If superinfection with a third strain occurs, then the incoming strain replaces one of the
previous strains in a manner that is proportional to the relative fitness of the pre-existing
strains. Parameter values were estimated from the literature. Simulations were run for 30
years after the introduction of treatment (IPT). They concluded that the use of IPT to
prevent the progression of latent M. tuberculosis in HIV-TB coinfected individuals could
reduce the burden of TB diesease and infection for a number of years but could also increase
the emergence of drug-resistant TB.
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2.5 Link between the review and this thesis
We intend to extend the model presented in [34] by adding another strain of TB which is
resistant to at least one of the first-line anti-tuberculosis drugs and include the possibility
of TB superinfection. We endeavour to evaluate the contribution of TB superinfection
on the prevalence and incidence of tuberculosis in HIV-negative and HIV-TB coinfected
individuals.
In relation to the interventions discussed in [12, 13, 34, 48, 56], we intend to study the
effectiveness of condom use, antiretroviral therapy (ART), isoniazid preventive therapy
(IPT) and increased TB detection on the control of TB and HIV in the presence of TB
superinfection.
The assumption taken in [7] that superinfection is only by resistant strains is not realistic.
In our case, we assume that an individual can be superinfected with either a resistant or a
sensitive strain. We also assume that an individual can not be actively infected with two
strains and progression to active disease after superinfection is independent of the strain
type.
Finally, we intend to keep the MTB and HIV infection rates varying depending on the
prevalence of individuals with active TB and HIV respectively. Making these two constant
as it was done in [13] may not be appropriate for sub-Saharan Africa where the burden of
TB and HIV is already high.
2.6 Conclusion
An understanding of the pathogenesis and epidemiology of TB and HIV, and the inter-
action between the two is essential in the development of mathematical models that can
predict the dynamics of the two epidemics. In this chapter we have reviewed some of the
mathematical models used to describe the transmission dynamics of TB and HIV. But
the model assumptions, the number of parameters and equations used differ, and a few of
them have been validated by experimental data. We acknowledge the limitations of data
for parameter estimations. This has an impact of limiting the use of the mathematical
Chapter 2. Literature review 17
models to real life scenarios. We now consider a two-strain TB model with superinfection
in the next chapter.
Chapter 3
The two-strain tuberculosis model
with superinfection
3.1 Introduction
In this chapter, we develop a simple model that describes the dynamics of the transmission
of tuberculosis in the presence of two strains. Our model is close to the one presented in
[39], but in our case, we add an extra compartment for those latently infected with two
strains. This model can also be viewed as an extension of the model presented in [34] in
the absence of HIV.
3.2 Model development
We denote the drug-sensitive strain by subscript 1 and the drug-resistant strain by subscript
2 and the mixed infection of both drug-resistant and drug-sensitive strains by subscript
12. The host population is divided into the following subgroups; susceptible (S), who
have never been exposed to the MTB bacteria; latent (E), those who are infected but
not infectious and infectious (I), those who are capable of transmitting the infection.
Individuals are born susceptible to infection at a constant rate B. Susceptible individuals
are infected with M. tuberculosis of either strain 1 or strain 2 at a rate that is proportional
to the prevalence of individuals with active TB of strain 1 or strain 2 respectively. A
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proportion p of individuals progress directly to active TB (move to state I) after primary
infection. The remaining proportion get latently infected with TB (move to state E).
Latently infected individuals acquire some protective immunity that reduces the risk of
getting another infection [31, 48]. We assume that individuals latently infected with TB
do not infect others. Individuals who have latent TB, for instance, those in state E1 can
either die due to natural causes or progress to active disease through exogenous reinfection
or endogenous reactivation or get reinfected with a different strain of TB (strain 2) at a rate
c. The process where by an individual is reinfected with a different strain of tuberculosis
is termed superinfection. After superinfection a proportion θ2 progress to active disease
and the remaining proportion remain latently infected with two strains (move to state
E12). Since we assume that primary infection induces some protection towards any other
incoming infection, we take the reinfection and superinfection parameters {q1, q2, c} ≤ p.
Individuals in state E2 have similar infection dynamics. Individuals latently infected with
two strains of tuberculosis, where one strain is drug-sensitive and the other is drug-resistant
can progress to active tuberculosis of the more fit strain. Recovery from active TB by
treatment or self-cure takes the individuals from state I to state E. The flows between the
different states (compartments) of the model are clearly shown in Fig. 3.1. Table. 3.1 shows
the model parameters and their definitions. Table. 3.2 shows some key epidemiological
definitions that are important in TB dynamics.
The following observations and assumptions are also essential in the development of the
model and numerical simulations.
 Individuals who are latently infected with TB are likely to be reinfected with a dif-
ferent strain of M. tuberculosis. The probability of getting another strain will always
be independent of whether an individual is already infected or not. An individual
who has been superinfected has a higher chance of progressing from the latent state
to the active state [28]. We will thus consider parameter values of reactivation from
latent TB to active TB for the state E12 to be higher than those for the states E1
and E2.
 All individuals with active TB are assumed to be either in state I1 or state I2.
Individuals in state I1 are either actively infected with TB of strain 1 or actively
infected with TB of strain 1 and latently infected with TB of strain 2. To clarify
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this assumption, let I10 denote the number of people with active TB of strain 1 only
and I12 denote the number of people with active TB of strain 1 and latently infected
with TB of strain 2. We take I1=I10+I12. Similarly, I2=I20+I21, where I20 denotes
the number of people with active TB of strain 2 only and I21 denotes the number of
people with active TB of strain 2 and latently infected with TB of strain 1. Strain
1 is easier to treat than strain 2 and individuals infected with strain 2 take a longer
period in the infectious class due to its low treatment rates [39].
 We do not differentiate between pulmonary TB and extra-pulmonary TB, smear-
positive or infectious TB and smear-negative or non-infectious TB, primary resis-
tance (resistance obtained when an individual is infected with a resistant strain) and
acquired resistance (resistance obtained as a result of treatment failure). The model
does not take into consideration age and sex of individuals.
The two-strain tuberculosis model with superinfection can be represented by the system
of ordinary differential equations:
dS
dt
=B − S(i1 + i2)− µS,
dE1
dt
=[(1− p)S − q1E1]i1 − (a1 + µ+ ci2)E1 + (1− τ1)b1I1,
dE2
dt
=[(1− p)S − q2E2]i2 − (a2 + µ+ ci1)E2 + (1− τ2)b2I2,
dE12
dt
=(1− θ1)cE2i1 + (1− θ2)cE1i2 − (ω1i1 + ω2i2 + σ1 + σ2 + µ)E12
+ τ1b1I1 + τ2b2I2,
dI1
dt
=(pS + q1E1 + θ1cE2 + ω1E12)i1 + a1E1 + σ1E12 − (b1 +m)I1,
dI2
dt
=(pS + q2E2 + θ2cE1 + ω2E12)i2 + a2E2 + σ2E12 − (b2 +m)I2,


(3.1)
where i1 = (k1I1)/P and i2 = (k2I2)/P . P is the total population which can be obtained
from
P = S + E1 + E2 + E12 + I1 + I2.
The rate of change of the population is given by the differential equation
dP
dt
= B − µP − δ(I1 + I2), (3.2)
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TABLE. 3.1. Definitions of the parameters used in the model.
B Birth rate;
µ Mortality rate for individuals without active TB;
m Mortality rate for individuals who have active TB. Note that m > µ;
k1, k2 MTB transmission rate;
p Proportion of individuals without TB that progress to active TB after primary
infection. The remaining proportion, 1− p acquire latent TB;
c Superinfection rate;
τ1, τ2 Proportion of individuals that move to state E12 after recovery;
θ1, θ2 Proportion of individuals that progress to active TB of the incoming strain
after superinfection. The remaining proportion remain latently infected with
two strains;
σ1, σ2 Rate at which individuals latently infected with two strains of TB progress to
active TB of either strain 1 or 2 through reactivation;
q1, q2 Rate at which individuals latently infected with one strain of TB progress to
active TB through reinfection;
ω1, ω2 Rate at which individuals latently infected with two strains of TB progress to
active disease through reinfection;
a1, a2 Rate at which individuals latently infected with one strain of TB progress to
active TB through reactivation;
β1, β2 Rate at which individuals with active TB recover without treatment;
γ1, γ2 Rate at which individuals with active TB are detected;
ε1, ε2 Proportion of individuals who have active TB that are detected and successfully
treated;
b1, b2 Recovery rate from active TB. Note that b1 = β1 + γ1ε1 and b2 = β2 + γ2ε2.
which is derived from adding all the equations in system (3.1), where δ = m− µ.
All the variables and parameters in the model (3.1) are considered to be positive and the
model lies in the feasible region (that is, where the model makes biological sense)
W =
{
(S,E1, E2, E12, I1, I2) ∈ R
6
+ : P ≤
B
µ
}
which can be shown to be positively invariant with respect to system (3.1).
Positivity and boundedness of solutions
It is necessary to prove that all the variables S,E1, E2, E12, I1 and I2 of model 3.1 are
non-negative all the time since the model describes human population.
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FIG. 3.1. The schematic representation of the two-strain TB model with superinfection.
Theorem 3.2.1 Let S(0) ≥ 0, E1(0) ≥ 0, E2(0) ≥ 0, E12(0) ≥ 0, I1(0) ≥ 0 and I2(0) ≥ 0.
The solutions S, E1, E2, E12, I1 and I2 of system (3.1) are positive for all t ≥ 0. For the
model system (3.1), the region W is positively invariant and all solutions starting in R6+
approach, enter, or stay in W .
Proof : It is easy to prove that the solutions of system (3.1) are positive for t ≥ 0 with
initial conditions in R6+ if not we assume for a contradiction that there exists a first time ts:
S(ts) = 0, S
′(ts) < 0 and S(t) > 0, E1(t) > 0, E2(t) > 0, E12(t) > 0, I1(t) > 0, I2(t) > 0 for
0 < t < ts or there exists a tu: E1(tu) = 0, E
′
1(tu) < 0 and S(t) > 0, E1(t) > 0, E2(t) > 0,
E12(t) > 0, I1(t) > 0, I2(t) > 0 for 0 < t < tu or there exists a tv: E2(tv) = 0, E
′
2(tv) < 0
and S(t) > 0, E1(t) > 0, E2(t) > 0, E12(t) > 0, I1(t) > 0, I2(t) > 0 for 0 < t < tv or
there exists a tx: E12(tx) = 0, E
′
12(tx) < 0 and S(t) > 0, E1(t) > 0, E2(t) > 0, E12(t) > 0,
I1(t) > 0, I2(t) > 0 for 0 < t < tx or there exists a ty: I1(ty) = 0, I
′
1(ty) < 0 and S(t) > 0,
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E1(t) > 0, E2(t) > 0, E12(t) > 0, I1(t) > 0, I2(t) > 0 for 0 < t < ty or there exists a tz:
I2(tz) = 0, I
′
2(tz) < 0 and S(t) > 0, E1(t) > 0, E2(t) > 0, E12(t) > 0, I1(t) > 0, I2(t) > 0
for 0 < t < tz.
Putting all the above assumptions into consideration, we obtain
S ′(ts) = B > 0,
E ′1(tu) = (1− p)S(tu)i1(tu) + (1− τ1)b1I1(tu) > 0,
E ′2(tv) = (1− p)S(tv)i2(tv) + (1− τ2)b2I2(tv) > 0,
E ′12(tx) = (1− θ1)cE2(tx)i1(tx) + (1− θ2)cE1(tx) + τ1b1I1(tx) + τ2b2I2(tx) > 0,
I ′1(ty) = a1E1(ty) + σ1E12(ty) > 0,
I ′2(tz) = a2E2(tz) + σ2E12(tz) > 0,
which gives a contradiction in all the six cases meaning that S, E1, E2, E12, I1 and I2
remain positive for t ≥ 0. Since P (t) ≥ I1(t) and P (t) ≥ I2(t), then
B − (µ+ δ)P (t) ≤ P ′(t) ≤ B − µP (t).
Thus, P (t) is bounded which implies that any solution of model 3.1 with initial conditions
in W stays there for t ≥ 0. 
In the absence of the disease (that is, δ = 0), then equation (3.2) reduces to
dP
dt
+ µP = B. (3.3)
Solving equation (3.3), we have
eµt
dP
dt
+ µeµtP = Beµt,
d
dt
(eµtP ) = Beµt,
where eµt is the integrating factor. Integrating both sides and rearranging, we have the
general solution to equation (3.2) as
P (t) =
B
µ
+ ξe−µt, (3.4)
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where ξ is a constant of integration.
Let P (0) = P0, then
ξ = P0 −
B
µ
,
⇒ P (t) = P0e
−µt +
B
µ
(1− e−µt).
From the above solution, it is clear that P (t) →
B
µ
as t → ∞. Thus system (3.1) will
always have the disease-free equilibrium (
B
µ
, 0, 0, 0, 0).
TABLE. 3.2. Similarity between the medical vocabulary and the two-strain TB model
with superinfection. Adopted from [34].
Total population P = S + E1 + E2 + E12 + I1 + I2
TB notification rate (γ1I1 + γ2I2)/P
MTB prevalence (E1 + E2 + E12 + I1 + I2)/P
TB prevalence (I1 + I2)/P
MTB infection rate k(I1 + I2)/P
TB cases T = a1E1 + a2E2 + σ1E12 + σ2E12 + {(pS + q1E1 + θ1cE2 +
ω1E12)k1I1 + (pS + q2E2 + θ2cE1 + ω2E12)k2I2}/P
TB incidence rate T/P
“Styblo’s ratio” 1,000×(TB incidence rate)/(MTB infection rate)
Reactivation (a1E1 + a2E2 + σ1E12 + σ2E12)/T
Reinfection {(q1E1 + ω1E12)k1I1 + (q2E2 + ω2E12)k2I2} /T/P
Superinfection (θ1cE2k1I1 + θ2cE1k2I2)/T/P
Primary disease pS(k1I1 + k2I2)/T/P
3.3 Mathematical analysis
Before carrying out the mathematical analysis of the whole model it is enlightening to
consider its submodels. We are able to gain insights into the dynamics of the whole model
by considering smaller models. We consider firstly, the TB model with one strain, by setting
E2 = E12 = I2 = 0. Secondly, we consider the TB model with two strains in the absence
of superinfection by setting E12 = 0. Thirdly, we consider the whole model. Qualitative
analysis of some models are not tractable and we resort to numerical simulations to obtain
insights into the dynamics of the model.
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3.3.1 Analysis of the one-strain TB model
In a case where there is one strain of tuberculosis and no superinfection, system (3.1)
reduces to,
dS
dt
= B − S
k1I1
N
− µS,
dE1
dt
= [(1− p)S − q1E1]
k1I1
N
− (a1 + µ)E1 + b1I1,
dI1
dt
= (pS + q1E1)
k1I1
N
+ a1E1 − (b1 +m)I1,


(3.5)
where N is the total population, given by N = S + E1 + I1. The model has a disease-free
equilibrium point X0 = (S
0, E01 , E
0
2) = (
B
µ
, 0, 0).
The dynamics of the one-strain TB model will be considered in
W0 =
{
(S,E1, I1) ∈ R
3
+ : N ≤
B
µ
}
which can be shown to be positively invariant with respect to system (3.5).
The equations given in system (3.5) are similar to the ones considered by Bacae˝r et al. [34]
for TB without HIV. In addition to other results, our analysis gives the global stability of
the disease-free equilibrium and the local stability of the endemic equilibrium. These two
results were not presented in [34].
The basic reproduction number
The basic reproduction number is defined as the average number of secondary infectious
cases that an infectious individual would generate during his/her infectious period in a
population that is wholly susceptible [7, 39, 51]. It is usually denoted by R0. If R0 < 1, then
on average, an infected individual produces less than one new infected individual over the
course of one’s infectious period, and thus the infection will not persist. On the other hand,
if R0 > 1, then on average an infected individual produces more than one new infected
individuals over the course of one’s infectious period and thus the disease will persist in
the population. For the case of a single infected compartment, R0 is simply the product of
the infection rate and the mean duration of the infection, but for more complicated models
with several infected compartments this simple definition is not enough. A more general
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basic reproduction number can be defined as the number of new infections produced by an
infectious individual in a susceptible population at a disease-free equilibrium [51].
Using the method presented in [51], we can write system (3.5) as
dX
dt
= f(X)
= F (X)− V (X)
= F (X)− (V −(X)− V +(X)),
where X = (S,E1, I1), F is the rate of appearance of new infections in each compartment,
V + is the rate of transfer into each compartment by all other means and V − is the rate
of transfer out of each compartment. Progression from E to I is not considered as a new
infection. Hence,
F =
(
(1− p)S k1I1
N
pS k1I1
N
)
and V =
(
q1E1
k1I1
N
+ (a1 + µ)E1 − b1I1
−q1E1
k1I1
N
− a1E1 + (b1 +m)I1
)
.
The derivatives DF (X0) and DV (X0) are partitioned according to Lemma 1 in [51] so
that
DF (X0) =
(
F 0
0 0
)
and DV (X0) =
(
V 0
J3 J4
)
,
where F and V are the matrices given by the derivatives of F and V with respect to the
infected classes evaluated at the disease-free equilibrium point X0 and given by
F =
(
0 (1− p)k1
0 pk1
)
and V =
(
a1 + µ −b1
−a1 b1 +m
)
.
The basic reproduction number is defined as the spectral radius of the next generation
matrix, FV −1. It is given by
RTB1 =
k1(a1 + pµ)
a1m+mµ+ µb1
, (3.6)
which is the same as the one obtained by Bacae˝r et al. [34].
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NOTE: The above reproduction number was obtained by considering the sensitive strain
only. Similarly, the analysis of the resistant strain leads to the reproduction number given
by
RTB2 =
k2(a2 + pµ)
a2m+mµ+ µb2
. (3.7)
Local stability of disease-free equilibrium X0
We need to show that if F is set to zero, then all the eigenvalues of Df(X0) have negative
real part for the disease-free equilibrium point X0 to be locally stable. This is in accordance
with A(5) of Theorem 2 in [51]. The Jacobian of f at X0 with F set to zero is,
J0 =


−µ 0 −k1
0 −(a1 + µ) b1
0 a1 −(b1 +m)

 .
The eigenvalues of the Jacobian are: -µ, −r1 ±
√
r21 − 4r0, where
r1 = µ+ b1 + a1 +m,
r0 = mµ+ b1µ+ a1m.
Since r1 and r0 are positive, then all eigenvalues have negative real part and thus the results
can be summarised in the Theorem given below.
Theorem 3.3.1 The disease-free equilibrium point X0 is locally asymptotically stable if
RTB1 < 1 and unstable if R
TB
1 > 1.
Global stability of disease-free equilibrium X0
Theorem 3.3.2 The disease-free equilibrium X0 = (
B
µ
, 0, 0) of system (3.5) is globally
asymptotically stable in W0 if R
TB
1 ≤ 1 and unstable if R
TB
1 > 1.
Proof. Consider the Lyapunov function
L = a1E1 + (a1 + µ)I1.
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Its derivative with time along the solutions of system (3.5) is
L′ =a1E
′
1 + (a1 + µ)I
′
1,
=a1[((1− p)S − q1E1)
k1I1
N
− (a1 + µ)E1 + b1I1] + (a1 + µ)[(pS + q1E1)
k1I1
N
+ a1E1 − (b1 +m)I1],
=
k1a1SI1
N
+
pk1µSI1
N
+
q1k1µE1I1
N
− [m(a1 + µ) + µb1]I1,
=
SI1k1(a1 + pµ)
N
− [m(a1 + µ) + µb1]I1 +
q1k1µE1I1
N
=
SI1(m(a1 + µ) + µb1)
N
[
k1(a1 + pµ)
(m(a1 + µ) + µb1)
− 1
]
+
q1k1µE1I1
N
,
≤
(m(a1 + µ) + µb1)
N
SI1
N
[
k1(a1 + pµ)
(m(a1 + µ) + µb1)
− 1
]
.
Since N ≥ S, then we can write that
L′ ≤ (m(a1 + µ) + µb1)
[
k1(a1 + pµ)
(m(a1 + µ) + µb1)
− 1
]
I1,
= (m(a1 + µ) + µb1)[R
TB
1 − 1]I1,
from which L′ ≤ 0 if RTB1 ≤ 1 and L
′ = 0 if RTB1 = 1. It is also clear that L
′ = 0 implies
that I1 = 0, which means that the disease-free equilibrium point is globally asymptotically
stable and thus the proof follows. 
The endemic steady states of the one-strain TB model
Let the endemic steady states be given by X∗ = (S∗, E∗1 , I
∗
1 ), with S
∗ > 0, E∗1 > 0, and
I∗1 > 0. By equating system (3.5) to zero and using the following notation
N∗ = S∗ + E∗1 + I
∗
1 , s
∗ = S∗/N∗, e∗1 = E
∗
1/N
∗, i∗1 = I
∗
1/N
∗, b = B/N∗,
s∗ + e∗1 + i
∗
1 = 1,

 (3.8)
we obtain
b− s∗k1i
∗
1 − µs
∗ = 0, (3.9)
((1− p)s∗ − q1e
∗
1)k1i
∗
1 − (a1 + µ)e
∗
1 + b1i
∗
1 = 0, (3.10)
(ps∗ + q1e
∗
1)k1i
∗
1 + a1e
∗
1 − (b1 +m)i
∗
1 = 0. (3.11)
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From equation (3.9), we can see that
s∗ =
b
k1i∗1 + µ
⇔ S∗ =
B
k1i∗1 + µ
. (3.12)
Adding equations (3.10) and (3.11) gives
s∗k1i
∗
1 − µe
∗
1 −mi
∗
1 = 0. (3.13)
Substituting for s∗ = 1− e∗1 − i
∗
1 in equation (3.13), we have
(1− e∗1 − i
∗
1)k1i
∗
1 − µe
∗
1 −mi
∗
1 = 0,
k1i
∗
1 − k1e
∗
1i
∗
1 − k1i
∗2
1 − µe
∗
1 −mi
∗
1 = 0,
which gives
e∗1 =
k1i
∗
1 −mi
∗
1 − k1i
∗2
1
k1i1 + µ
. (3.14)
Substituting for e∗1 in equation (3.11) and using the fact that s
∗ = 1− e∗1 − i
∗
1, we obtain
i∗1 {(k1 −m− k1i
∗
1)(q1k1i
∗
1 + a1 − pk1i
∗
1) + (k1i
∗
1 + µ)(pk1 − pk1i
∗
1 − b1 −m)} = 0.
This implies that i∗1 = 0, or
((k1 −m)− k1i
∗
1)((q1k1 − pk1)i
∗
1 + a1) + (k1i
∗
1 + µ)((pk1 − b1 −m) + pk1i
∗
1) = 0. (3.15)
The case i∗1 = 0 corresponds to the disease-free equilibrium X0. Simplifying equation
(3.15), we obtain the polynomial
C(i∗1) = i
∗2
1 + C1i
∗
1 + C0 = 0, (3.16)
where C1 =
(mq1 −mp− q1k1 + a1 + b1 +m+ pµ)
q1k1
and C0 =
ma1 + b1µ+mµ− k1(a1 + pµ)
q1k21
.
The simplification of C0 gives C0 =
ma1 + b1µ+mµ
q1k21
(1−RTB1 ), where R
TB
1 =
k1(a1 + pµ)
ma1 + b1µ+mµ
.
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After finding i∗1, we can also compute e
∗
1 using equation (3.14), S
∗ using equation (3.12)
and the other steady states from
s∗ = 1− e∗1 − i
∗
1, N
∗ = S∗/s∗, E∗1 = e
∗
1N
∗, I∗1 = i
∗
1N
∗. (3.17)
It is clear that if RTB1 > 1, then C0 < 0 and if R
TB
1 < 1, then C0 > 0. Equation (3.16) has
a solution given by
i∗1 =
−C1 ±
√
C21 − 4C0
2
(3.18)
Note that:
(i). If C1 > 0 and C0 < 0, then equation (3.18) has one positive solution.
(ii). If C1 > 0 and C0 > 0, then equation (3.18) has two negative solutions.
(iii). If C1 < 0 and C0 < 0, then equation (3.18) has one positive solution.
(iv). If C1 < 0 and C0 > 0, then equation (3.18) has two positive solutions.
We thus have the following Theorem on the existence of the endemic steady states.
Theorem 3.3.3 The endemic steady state X∗ exists and
(i) for any C1 and R
TB
1 > 1, then system (3.5) has one endemic equilibrium point;
(ii) if C1 < 0 and R
TB
1 < 1, then system (3.5) has two endemic equilibria.
Local stability of endemic equilibrium
We will use the center manifold theory which is described in [6] (Theorem 4.1) and [36]
(Theorem 3.6). The theory is used to determine the local stability of a nonhyperbolic
equilibrium and the type of bifurcation that occurs. We present it here for the purpose of
easier referencing.
Theorem 3.3.4 Consider the following general system of ordinary differential equations
with a parameter φ
dx
dt
= f(x, φ), f : Rn ×R → R and f ∈ C2(Rn × R), (3.19)
where 0 is an equilibrium point of the system (that is, f(0, φ) ≡ 0 for all φ) and assume
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A1 : A = Dxf(0, 0) = (
∂fi
dxi
(0, 0)) is the linearization matrix of the system (3.5) around
the equilibrium 0 with φ evaluated at 0. Zero is a simple eigenvalue of A and other
eigenvalues of A have negative real parts;
A2 : Matrix A has a right eigenvector w and a left eigenvector v (each corresponding to
the zero eigenvalue).
Let fr be the rth component of f and
a =
n∑
r,i,j=1
vrwiwj
∂2fr
∂xi∂xj
(0, 0),
b =
n∑
r,i=1
vrwi
∂2fr
∂xi∂φ
(0, 0).
The local dynamics of the system around 0 is totally determined by the signs of a and b.
i : a > 0, b > 0. When φ < 0 with |φ| ≪ 1, 0 is locally asymptotically stable and there
exists a positive unstable equilibrium; when 0 < φ≪ 1, 0 is unstable and there exists
a negative, locally asymptotically stable equilibrium;
ii : a < 0, b < 0. When φ < 0 with |φ| ≪ 1, 0 is unstable; when 0 < φ≪ 1, 0 is locally
asymptotically stable equilibrium, and there exists a positive unstable equilibrium;
iii : a > 0, b < 0. When φ < 0 with |φ| ≪ 1, 0 is unstable, and there exists a locally
asymptotically stable negative equilibrium; when |φ| ≪ 1, 0 is stable, and a positive
unstable equilibrium appears;
iv : a < 0, b > 0. When φ changes from negative to positive, 0 changes its stability from
stable to unstable. Correspondingly a negative unstable equilibrium becomes positive
and locally asymptotically stable.
Particularly, if a > 0 and b > 0, then a backward bifurcation occurs at φ = 0.
To apply this method, it is necessary to make a change of variables. Let S = x1, E1 =
x2, I1 = x3 and N = x1 + x2 + x3. After this change of variables, our X and
dX
dt
becomes
X = (x1, x2, x3) and
dX
dt
= f = (f1, f2, f3) respectively. The disease-free equilibrium
remains unchanged and is given by X0 = (
B
µ
, 0, 0). System (3.5) can now be re-written as
dx1
dt
= f1 = B −
k1x1x3
x1 + x2 + x3
− µx1,
dx2
dt
= f2 =
(1− p)k1x1x3
x1 + x2 + x3
−
q1k1x2x3
x1 + x2 + x3
− (a1 + µ)x2 + b1x3,
dx3
dt
= f3 =
pk1x1x3
x1 + x2 + x3
+
q1k1x2x3
x1 + x2 + x3
+ a1x2 − (b1 +m)x3.


(3.20)
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The Jacobian of system (3.20) at X0 is given by
J(X0) =


−µ 0 −k1
0 −(a1 + µ) (1− p)k1 + b1
0 a1 pk1 − (b1 +m)

 .
We can also determine RTB1 by evaluating the eigenvalues of J(X0). We note that it is
equivalent to the one given in equation (3.6). Consider the case when RTB1 = 1 and assume
that k1 is the bifurcation parameter. Solving equation (3.6) for k1 when R
TB
1 = 1, gives
k1 = k
∗
1 =
a1m+mµ+ µb1
a1 + pµ
. (3.21)
Note that: If k1 < k
∗
1, then R
TB
1 < 1 and if k1 > k
∗
1, then R
TB
1 > 1.
The Jacobian of (3.20) at k1 = k
∗
1, denoted by Jk∗1 has the following eigenvalues.(
0,−µ,
mpa1 − pµ
2 −ma1 − µa1 − pµa1 − a
2
1 − a1b1
pµ+ a1
)
.
The right eigenvector (associated with the zero eigenvalue) of this Jacobian is given by
w = [w1, w2, w3]
T , where
w1 = −
mµ+ma1 + µb1
µ(pµ+ a1)
,
w2 =
m(1− p) + b1
pµ+ a1
,
w3 = 1.
Jk∗
1
also has a left eigenvector (associated with the zero eigenvalue) given by v = [v1, v2, v3]
T ,
where
v1 = 0,
v2 =
a1
µ+ a1
,
v3 = 1.
To compute a, we need to look for all the non-zero partial derivatives of f at the disease-
free equilibrium (as in Theorem 3.3.4). Since v1 = 0, then the partial derivatives of f1 are
not necessary since they will cancel out after substitution. The non-zero partial derivatives
of f2 and f3 of system (3.20) are given by
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∂2f2
∂x2∂x3
=
−k∗1µ(1− p+ q1)
B
,
∂2f2
∂x3∂x2
=
−k∗1µ(1− p + q1)
B
,
∂2f2
∂x23
=
−2k∗1µ(1− p)
B
,
∂2f3
∂x2∂x3
=
k∗1µ(q1 − p)
B
,
∂2f3
∂x3∂x2
=
k∗1µ(q1 − p)
B
,
∂2f3
∂x23
=
−2k∗1pµ
B
.
Using the above expressions and making substitutions for a, we obtain
a = v2w2w3
∂2f2
∂x2∂x3
+ v2w3w2
∂2f2
∂x3∂x2
+ v2w
2
3
∂2f2
∂x23
+ v3w2w3
∂2f3
∂x2∂x3
+ v3w3w2
∂2f3
∂x3∂x2
+ v3w
2
3
∂2f3
∂x23
,
= −
2k∗1µa1(m(1 − p) + b1)(1 − p + q1)
B(µ + a1)(pµ + a1)
−
2k∗1µa1(1− p)
B(µ + a1)
−
2k∗1µ(m(1− p) + b1)(p− q1)
B(pµ+ a1)
−
2k∗1pµ
B
,
=
−2k∗1µ
B
{
a1(m(1− p) + b1)(1 − p + q1)
(µ + a1)(pµ + a1)
+
a1(1− p)
(µ + a1)
+
(m(1− p) + b1)(p − q1)
(pµ + a1)
+ p
}
,
from which a < 0 since q1 ≤ p.
For the computation of b, we also need to look for the non-zero partial derivatives of f
at the disease-free equilibrium (as in Theorem 3.3.4). We are also neglecting the partial
derivatives of f1 since v1 = 0. Thus, the other non-zero partial derivatives are given by
∂2f2
∂x3∂k
∗
1
= (1− p),
∂2f3
∂x3∂k
∗
1
= p.
It follows from the above expressions that
b = v2w3
∂2f2
∂x3∂k∗1
+ v3w3
∂2f3
∂x3∂k∗1
,
=
a1
(µ+ a1)
(m(1− p) + b1)
(pµ+ a1)
(1− p) +
(m(1− p) + b1)
(pµ+ a1)
p,
=
(m(1− p) + b1)(pµ+ a1)
(µ+ a1)(pµ+ a1)
,
=
(m(1− p) + b1)
(µ+ a1)
> 0.
Thus, the results obtained from the above analysis can be summarised in the Theorem
below.
Theorem 3.3.5 The unique endemic equilibrium of the one-strain TB model represented
by system (3.5) is locally asymptotically stable for RTB1 > 1, with R
TB
1 close to 1.
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Feng et al. [54] had a model which is almost similar to this one with one extra compart-
ment for treatment. In their model, a backward bifurcation occurred when the values of
exogenous reinfection were high. It can also be noticed that for high values of q1 (exogenous
reinfection), then the value of a would be greater than zero and according to Theorem 3.3.4
a backward bifurcation would occur since b > 0 giving a similar result to the one obtained
by Feng et al. [54]. Sharomi et al. [36] noted that models of TB dynamics with exogenous
reinfection are known to exhibit the phenomenon of backward bifurcation. They did the
same analysis in their HIV-TB model after analysing the TB-only sub-model and detected
a backward bifurcation by taking the reinfection parameter to be 3 per year which is gen-
erally high. Since it is believed that after primary infection there is a protection induced
towards any other incoming infection [31], then we should expect q1 ≤ p as it was done in
[34, 39].
3.3.2 Analysis of the two-strain TB model without superinfec-
tion
We now consider a two-strain TB model in the absence of superinfection. In this case
E12 = 0, and system (3.1) reduces to,
dS
dt
= B − S
(k1I1 + k2I2)
Q
− µS,
dE1
dt
= [(1− p)S − q1E1]
k1I1
Q
− (a1 + µ)E1 + b1I1,
dE2
dt
= [(1− p)S − q2E2]
k2I2
Q
− (a2 + µ)E2 + b2I2,
dI1
dt
= (pS + q1E1)
k1I1
Q
+ a1E1 − (b1 +m)I1,
dI2
dt
= (pS + q2E2)
k2I2
Q
+ a2E2 − (b2 +m)I2,


(3.22)
where Q is the total population, given by Q = S + E1 + E2 + I1 + I2.
The dynamics of the two-strain TB model will be considered in
W1 =
{
(S,E1, E2, I1, I2) ∈ R
5
+ : Q ≤
B
µ
}
which can be shown to be positively invariant with respect to system (3.22).
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System (3.22) is comparable to the model considered by Rodrigues et al. [39] without
treatment failure and superinfection by resistant strains.
The basic reproduction number
Again using the method in subsection (3.3.1) with dX
dt
= f(X), where X is now given
by (S,E1, E2, I1, I2) and the disease-free equilibrium X1 = (
B
µ
, 0, 0, 0, 0), we obtain the
following new expressions for F ,V , F and V .
F =


(1− p)S k1I1
Q
(1− p)S k2I2
Q
pS k1I1
Q
pS k2I2
Q

, V =


q1E1
k1I1
Q
+ (a1 + µ)E1 − b1I1
q2E2
k2I2
Q
+ (a2 + µ)E2 − b2I2
−q1E1
k1I1
Q
− a1E1 + (b1 +m)I1
−q2E2
k2I2
Q
− a2E2 + (b2 +m)I2

,
F =


0 0 (1− p)k1 0
0 0 0 (1− p)k2
0 0 pk1 0
0 0 0 pk2

 and V =


a1 + µ 0 −b1 0
0 a2 + µ 0 −b2
−a1 0 b1 +m 0
0 −a2 0 b2 +m

 .
The basic reproduction number, RTB0 of the two-strain TB model is also defined as the
spectral radius of the next generation matrix FV −1 and is given by RTB0 =max(R
TB
1 , R
TB
2 ),
where
RTB1 =
k1(a1 + µp)
(m+ b1)µ+ a1m
(3.23)
and
RTB2 =
k2(a2 + µp)
(m+ b2)µ+ a2m
. (3.24)
This basic reproduction number compares well with the one obtained by Rodrigues et al.
[39] if treatment failure is not put into consideration.
Local stability of disease-free equilibrium X1
The Jacobian of f at X1 with F set to zero is
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J1 =


−µ 0 0 −k1 −k2
0 −(a1 + µ) 0 b1 0
0 0 −(a2 + µ) 0 b2
0 a1 0 −(b1 +m) 0
0 0 a2 0 −(b2 +m)


.
The eigenvalues of the Jacobian are: -µ, −y1 ±
√
y21 − 4y0, −z1 ±
√
z21 − 4z0, where
y1 = µ+m+ b1 + a1,
y0 = µm+ b1µ+ a1m,
z1 = µ+m+ b2 + a2,
z0 = µm+ b2µ+ a2m.
Since y1, y0, z1, z0 are positive, then all eigenvalues have real negative part and the results
can be summarised in the Theorem below.
Theorem 3.3.6 If RTB0 < 1, the disease-free equilibrium point X1 is locally asymptotically
stable and unstable if RTB0 > 1.
The computation of the endemic equilibrium of system (3.22) leads to a polynomial of
degree five which is difficult to analyse analytically. We thus resort to numerical results
which are given in section 3.4.
3.3.3 Analysis of the two-strain TB model with superinfection
After putting superinfection into consideration we obtain the new model which is schemat-
ically represented by Figure 3.1 and given by system (3.1).
As already explained in the model development in section 3.2, τ1 and τ2 denote the pro-
portion of individuals who move to respectively states E1 and E2 after recovery. These
proportions depend on the number of superinfected individuals that eventually progress
to active disease of either strain 1 or strain 2. If τ1 is much higher than τ2, it will imply
that most individuals progress to active TB of strain 1 after superinfection. Conversely,
if the number of individuals progressing to active disease of strain 2 after superinfection
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is high, then τ2 will be much greater than τ1. Our analysis will first be based on the
assumption that progression to active disease in one of the strains after superinfection is
much higher than the other. Later we will consider the case where individuals after super-
infection progress to either strain 1 or strain 2 at an approximately equal rate. Rodrigues
et al. [39] assumed that when an individual is infected with both drug-sensitive and drug-
resistant strains, he/she progresses to active tuberculosis of the drug-resistant strain. Our
assumption in the first analysis of this model does not differ from theirs, only that we are
considering progression to active TB of either a drug-sensitive or a drug-resistant strain of
active tuberculosis after superinfection.
In a case where most individuals progress to active TB of strain 1 after superinfection,
that is τ1 >> τ2, we can generally say that τ1 > 0 and τ2 ≃ 0. Using the method in
subsection (3.3.1) with dX
dt
= f(X), where X is now given by (S,E1, E2, E12, I1, I2) and the
disease-free equilibrium X2 = (
B
µ
, 0, 0, 0, 0, 0), we obtain the following new expressions for
F ,V , F and V .
F =


(1− p)S k1I1
P
(1− p)S k2I2
P
0
pS k1I1
P
pS k2I2
P


,
V =


q1E1
k1I1
P
+ (a1 + µ+ c
k2I2
P
)E1 − (1− τ1)b1I1
q2E2
k2I2
P
+ (a2 + µ+
k1I1
P
)E2 − b2I2
−(1− θ1)cE2
k1I1
P
− (1− θ2)cE1
k2I2
P
+ (ω1
k1I1
P
+ ω2
k2I2
P
+ σ1 + σ2 + µ)E12 − τ1b1I1
−(q1E1 + θ1cE2 + ω1E12)
k1I1
P
− a1E1 − σ1E12 + (b1 +m)I1
−(q2E2 + θ2cE1 + ω2E12)
k2I2
P
− a2E2 − σ2E12 + (b2 +m)I2


,
F =


0 0 0 (1− p)k1 0
0 0 0 0 (1− p)k2
0 0 0 0 0
0 0 0 pk1 0
0 0 0 0 pk2


and
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V =


a1 + µ 0 0 −(1− τ1)b1 0
0 a2 + µ 0 0 −b2
0 0 σ1 + σ2 + µ −τ1b1 0
−a1 0 −σ1 b1 +m 0
0 −a2 −σ2 0 b2 +m


.
The basic reproduction number, RTB0s (τ1, 0) of the two-strain TB model with superinfection
is also defined as the spectral radius of the next generation matrix FV −1 and is given by
RTB0s (τ1, 0)=max(R
TB
01 , R
TB
02 ), where
RTB01 =
k1(pµ+ a1)(µ+ σ1 + σ2)
m(µ+ a1)(µ+ σ1 + σ2) + b1[(µ+ σ2)(µ+ τ1a1) + µσ1(1− τ1)]
, (3.25)
and
RTB02 =
k2(a2 + µp)
(m+ b2)µ+ a2m
. (3.26)
Similarly, in a case where most individuals progress to active TB of strain 2 after superinfec-
tion, the basic reproduction number RTB0s (0, τ2) will be given byR
TB
0s (0, τ2)=max(R
TB
10 , R
TB
20 ),
where
RTB10 =
k1(a1 + µp)
(m+ b1)µ+ a1m
(3.27)
and
RTB20 =
k2(pµ+ a2)(µ+ σ1 + σ2)
m(µ+ a2)(µ+ σ1 + σ2) + b2[(µ+ σ1)(µ+ τ2a2) + µσ2(1− τ2)]
. (3.28)
Note that when τ1 = τ2 = 0, then the reproduction numbers R
TB
0s (τ1, 0) and R
TB
0s (0, τ2)
reduce to RTB1 and R
TB
2 respectively.
Finally, when τ1 > 0 and τ2 > 0 (assuming that individuals after superinfection progress
to either strain 1 or strain 2), the basic reproduction number RTB0s (τ1, τ2) is given by the
spectral radius of the matrix ML−1, where
M =


0 0 0 (1− p)k1 0
0 0 0 0 (1− p)k2
0 0 0 0 0
0 0 0 pk1 0
0 0 0 0 pk2


and
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L =


a1 + µ 0 0 −(1− τ1)b1 0
0 a2 + µ 0 0 −(1− τ2)b2
0 0 σ1 + σ2 + µ −τ1b1 −τ2b2
−a1 0 −σ1 b1 +m 0
0 −a2 −σ2 0 b2 +m


.
3.3.4 Analysis of the basic reproduction numbers, RTB0s (τ1, 0), R
TB
0s (0, τ2)
and RTB0s (τ1, τ2)
We need to investigate whether superinfection has a positive or negative impact on the three
basic reproduction numbers obtained in the previous subsection. Thus, we need to show if
RTB0s (τ1, 0) and R
TB
0s (0, τ2) increase or decrease with any increase in τ1 and τ2 respectively
for the first two reproduction numbers of the two-strain TB model with superinfection.
Differentiating RTB0s (τ1, 0) with respect to τ1 gives
∂RTB0s (τ1, 0)
∂τ1
=
k1b1(pµ+ a1)(µ+ σ1 + σ2)(µσ1 − a1(µ+ σ2))
{m(µ+ a1)(µ+ σ1 + σ2) + b1[(µ+ σ2)(µ+ τ1a1) + µσ1(1− τ1)]}2
,
from which
∂RTB0s (τ1, 0)
∂τ1
> 0 if µσ1 > a1(µ+ σ2).
Also, differentiating RTB0s (0, τ2) with respect to τ2 gives
∂RTB0s (0, τ2)
∂τ2
=
k2b2(pµ+ a2)(µ+ σ1 + σ2)(µσ2 − a2(µ+ σ1))
{m(µ+ a2)(µ+ σ1 + σ2) + b2[(µ+ σ1)(µ+ τ2a2) + µσ2(1− τ2)]}2
,
from which
∂RTB0s (0, τ2)
∂τ2
> 0 if µσ2 > a2(µ+ σ1).
Numerical results of the three basic reproduction numbers are shown in Fig. 3.2. Fig.
3.2 (a) shows that RTB0s (τ1, 0) will always be higher than R
TB
0s (0, τ2) and the two basic
reproduction numbers increase with any increase in τ1 and τ2 respectively. This implies
that progression to active TB of the drug-sensitive strain after superinfection drives the
TB epidemic at a slightly higher rate compared to progression to active TB of the drug-
resistant strain after superinfection. This result is due to the fact that the transmission
rate of sensitive strains was taken to be higher than that of resistant strains. On the other
hand, if the transmission rate of resistant strains is higher than that of sensitive strains,
then progression to active TB of the resistant strain after superinfection accelerates the
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epidemic at a much higher rate than progression to active TB of the sensitive strain and
RTB0s (0, τ2) will always be higher than R
TB
0s (τ1, 0). Fig. 3.2 (b) shows that an increase in
both τ1 and τ2 results in a higher increase in the basic reproduction number R
TB
0s (τ1, τ2).
 1.1
 1.2
 1.3
 1.4
 1.5
 1.6
 1.7
 1.8
 1.9
 2
 2.1
 0  0.1  0.2  0.3  0.4  0.5  0.6  0.7  0.8  0.9  1
RTB0s (τ1, 0)
RTB0s (0, τ2)
τ1 or τ2
R
T
B
0
s
(a)
 0
 0.1
 0.2
 0.3
 0.4
 0.5
 0.6
 0.7
 0.8
 0.9
 1  0
 0.1
 0.2
 0.3
 0.4
 0.5
 0.6
 0.7
 0.8
 0.9
 1
 1.7
 1.8
 1.9
 2
 2.1
 2.2
 2.3
R
T
B
0
s
(τ
1
,τ
2
)
R
T
B
0
s
(τ
1
,τ
2
)
τ1
τ2
(b)
FIG. 3.2. Plots of RTB0s against τ1 or τ2 (a) and R
TB
0s (τ1, τ2) against τ1 and τ2 (b). Parameter
values are given in Table 3.3.
3.4 Numerical simulations
3.4.1 Estimation of parameter values
In this section, we give the parameters that we used in our numerical simulations. Most of
the parameters were picked from the literature as explained in the following subsections.
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Demographic parameters
The natural mortality was taken to be µ=0.02/yr as in [34, 48, 49], corresponding to a life
expectancy of 50 years. Ssematimba et al. [2] took the life expectancy to be 45 years in
their TB analysis in Uganda. This mortality was assumed to be 0.014/yr in [33, 39, 55],
0.016/yr in [54], 0.0081 in [13]. These values give a very high life expectancy and therefore
will not be considered in our simulations.
TB parameters
Infection and mortality. We assume that the MTB infection rate is given by the product
of the active TB prevalence and the MTB transmission rate. The MTB transmission rate
was taken to be 15/yr as in [11] for the drug-sensitive strain and 8 per year as in [8] for the
drug-resistant strain. These values are on average close to 11.4/yr which was obtained in
[34] after fitting their model with data from a South African township by considering one
strain of TB which also lies in the range given in [11]. This value was taken to be 13/yr in
[7, 46] for drug-sensitive tuberculosis. This value was assumed to lie in the range 5-15 per
year in [11] for drug-sensitive tuberculosis and 7.0-12.6 per year in [8] for drug-resistant
tuberculosis.
The mortality for people with active TB was assumed to be 0.25/yr as in [34] (citing [48]).
This value was assumed to be 0.2/yr in [39], 0.3/yr in [8], 0.365/yr in [2]. It was also taken
to lie in the range 0.058-0.461 per year in [46].
Fast progression. We are taking the fraction of individuals who progress to active TB
after primary infection to be 11% as in [34] (citing [14]). We are taking the same value for
the two strains. This value was taken to be 10% in [31, 39], 5% in [13] for drug-sensitive
TB, 14% in [49] (citing [8] and other reference) for multidrug- resistant TB and it was also
taken to lie in the range 0.08-0.25 per year in [8] for drug-resistant TB.
Reinfection and superinfection. The rate at which individuals get reinfected or super-
infected was considered to be the same and given by q1 = q2 = c = ω1 = ω2 = 0.25p as in
[11] and [39] (citing [31]), where p is the probability of progressing to active TB after pri-
mary infection. Reinfection and superinfection are considered to be post primary infections
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and thus can be taken to be the same. In this case the partial immunity acquired from the
previous infection is 75%. Cohen and Murray [49] took this value to be 65% (citing [8] and
other references) for both drug-sensitive and multidrug-resistant TB. This value was also
assumed to lie in the range 50-100% in [10] (citing [11]). Feng et al. assumed a reinfection
risk factor of 30%, taking the partial immunity acquired from the primary infection to be
70%.
Reactivation. The reactivation rate was taken to be 0.000113/yr in [11] (citing [14] and
other references), 0.0003/yr in [34] (citing [14]), 0.005/yr in [54] (citing [46]), 0.0002/yr
in [39] (citing [31]) for both drug-sensitive and drug-resistant TB, 0.000299/yr in [14] (by
fitting data) for individuals older than 20 years. This value was also taken to lie in the
range 0.00256-0.00527 per year in [46] as a progression to TB within 20 years, 0.0001-0.0003
per year in [8]. We are taking the reactivation rate to be 0.0003/yr as in [8, 34] for both
strains. Individuals latently infected with two strains are estimated to have a relatively
higher reactivation rate of 0.008/yr since they are at a greater risk of developing active
disease [28].
Detection, recovery without treatment and successful treatment. The detection
rate was taken to be 0.74/yr in [34] (citing [40]) for drug-sensitive TB, 0.5/yr in [11] for
both drug-resistant and drug-sensitive TB. This value was taken to vary within the range
0.5-1.0 per year in [8] and after their numerical analysis, they concluded that the required
value should be 0.7/yr in order to interrupt the transmission cycle if a cure rate of 80% is
maintained for drug-resistant TB. We are taking this value to be 0.74/yr as in [34] for the
drug-sensitive strain and 0.7/yr as in [8] for the drug-resistant strain.
Self-cure of active cases was taken to be 0.2/yr in [11] for both drug-resistant and drug-
sensitive TB, 0.25/yr in [34] (citing [15]) for drug-sensitive TB, 0.2/yr in [49] (citing [8]) for
multidrug-resistant TB. This value was also taken to lie within the range 0.15-0.25 per year
in [8] for drug-resistant TB. We took this value to be 0.25/yr as in [34] for drug-sensitive
TB and 0.2/yr as in [8, 11] for drug-resistant TB.
Successful treatment for detected cases was taken to be 85% for drug-sensitive TB and 73%
for drug-resistant TB in [11], 80% in [34] (citing [40]) for drug-sensitive TB. The treatment
efficacy for drug-resistant TB was considered to 47% in [49]. We take this value to be 80%
as in [8, 34] for drug-sensitive TB and 47% as in [49] for drug-resistant TB.
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With these chosen values, we get b1 ≃ 0.84/yr and b2 ≃ 0.53/yr as recovery rates for drug-
sensitive and drug-resistant TB respectively. These recovery rates are reasonable since
recovery results to an individual moving from the active TB state to the latent TB state.
Notice that drug-resistant TB has a lower recovery rate since its treatment is known to be
difficult. For comparison, Guwatudde et al. [13] assumed a cure rate of 0.5/yr for drug-
sensitive TB, Rodrigues et al. [39] assumed a treatment rate of 2/yr for drug-sensitive
TB and 1.5/yr for drug-resistant TB, Ssematimba et al. [2] assumed a recovery rate of
1.5/yr for drug-sensitive TB, castillo-Chavez et al. [7] assumed a treatment rate of 2/yr
for drug-sensitive TB and 1/yr for drug-resistant TB.
The respective tuberculosis detection probabilities are given by
γ1
γ1 + β1 +m
≃ 60% and
γ2
γ2 + β2 +m
≃ 61%
for strain 1 and strain 2, which are almost the same. The respective average durations of
the disease are also given by
1
b1 +m
≃ 0.9 year and
1
b2 +m
≃ 1.3 years
for strain 1 and strain 2, giving a difference of 5 months. This implies that the period of
infectiousness of a resistant TB case is on average 5 months longer than that of a sensitive
TB case.
3.4.2 Simulations of one-strain TB model
The dynamical parameters listed in Table. 3.3 were used to produce the numerical results
in each of the three categories as considered in the mathematical analysis (that is, one-
strain TB model, two-strain TB model with and without superinfection). It was assumed
that S0 = 10, 000 [34] giving a value of B = 200/yr. The numerical results of one-strain
TB model with the fixed parameters given in Table. 3.3 show that
RTB1 ≃ 1.71, R
TB
2 ≃ 1.28.
Chapter 3. The two-strain tuberculosis model with superinfection 44
TABLE. 3.3. The parameter values for the two-strain TB model with superinfection.
Parameter definition Value Reference
Birth rate B 200/yr [34] (citing [45])
Natural mortality µ 0.02/yr [48, 49]
TB mortality m 0.25/yr [34]
MTB transmission rate k1, k2 15/yr, 8/yr [11], [8]
TB infection -fast progression p 11% [34]
Reactivation a1, a2 0.0003/yr [8, 34]
σ1, σ2 0.008/yr Estimated
Reinfection q1, q2 0.25p [11, 39]
ω1, ω2 0.25p [11, 39]
Superinfection c 0.25p [11, 39]
Recovery without treatment β1, β2 0.25/yr, 0.2/yr [8], [8, 11]
Detection rate γ1, γ2 0.74/yr, 0.7/yr [34], [8]
Treatment ε1, ε2 80%, 47% [8, 34], [49]
Proportion of individuals that are latently in-
fected with TB of strain 2 who progress to ac-
tive TB of strain 1 after being superinfected
with TB of strain 1
θ1 60% Estimated
Proportion of individuals that are latently in-
fected with TB of strain 1 who progress to ac-
tive TB of strain 2 after being superinfected
with TB of strain 2
θ2 60% Estimated
Proportion of individuals that are actively in-
fected with TB of strain 1 and latently in-
fected with TB of strain 2 that enter state
E12 after treatment
τ1 50% Estimated
Proportion of individuals that are actively in-
fected with TB of strain 2 and latently in-
fected with TB of strain 1 that enter state
E12 after treatment
τ2 50% Estimated
These values are close to 1.3 that was obtained in [34]. Blower et al. [46] developed a
model of the same dynamics and obtained a value which lies in the range 0.74-18.58 with
a median of 4.47, mean of 5.26 and standard deviation of 2.82. We first simulated system
(3.5) starting from the initial condition
S(t0) = S
∗, E1(t0) = E
∗
1 , I1(t0) = I
∗
1 ,
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FIG. 3.3. The individual population size of each class. Actively infected (a), latently
infected (b) and susceptible (c). Parameter values are given in Table 3.3.
where S∗, E∗1 , I
∗
1 are the endemic steady states of the one-strain TB model which can
be obtained from equations (3.12) and (3.17). The simulations were run up to a point
when a steady state was obtained. Fig .3.3 shows the individual population size of the
susceptible, latently infected and the infected classes. Due to the fact that strain 1 has
a higher reproduction number (that is, RTB1 > R
TB
2 ), it can be noticed that the size of
infected individuals of strain 1 is higher than that of strain 2. Fig. 3.4 shows the simulation
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FIG. 3.4. The simulation curves for the TB notification rate (a), TB incidence rate (b),
TB prevalence (c) and MTB infection rate (d) of the one-strain TB model. Parameter
values are given in Table 3.3.
curves for the TB notification rate, TB incidence rate, TB prevalence and MTB infection
rate against time in years. It was also observed that strain 1 has higher rates since its
reproduction number is greater than that of strain 2. The steady state values of strain 1
were used as the initial conditions in the simulation of the two-strain TB model with and
without superinfection. Table. 3.4 shows the characteristics of the endemic steady state of
the one-strain TB model.
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3.4.3 Simulations of two-strain TB model with and without su-
perinfection
The numerical results of the two cases (that is, the two-strain TB model and with and
without superinfection) with the fixed parameters given in Table. 3.3 and τ1 = τ2 = 0.5
show that
RTB0 ≃ 1.71, R
TB
0s (τ1, 0) ≃ 1.86, R
TB
0s (0, τ2) ≃ 1.23, R
TB
0s (τ1, τ2) ≃ 1.91.
These values are in the same range as the ones obtained in [7] in their two-strain TB model,
which are in the range 1.34-4.13.
We also present the simulation curves of the two cases (that is, the two strain TB model
with and without superinfection). These two cases are represented by system (3.1) and
(3.22) respectively. Our aim is to evaluate the impact of superinfection on the transmission
of tuberculosis. The initial conditions for susceptible, latently infected and actively infected
individuals of the drug-sensitive strain were taken to be the same as the steady state values
of the one-strain TB model which are give in Table. 3.4. We introduce two individuals
infected with a drug-resistant strain into a population where the the sensitive strains have
reached a steady state. We assume that one individual is harbouring a latent infection
and the other is actively infected. We assume that 60% of those superinfected progress
to active TB of the incoming strain soon after superinfection and the other 40% remain
latently infected with two strains of TB. We also assume that the proportion of individuals
who move to state E12 from I1 and I2 after treatment are the same and equal to 50% (that
is, τ1 = τ2 = 0.5).
3.4.4 The impact of superinfection on tuberculosis
Fig. 3.5 shows the simulation curves for the TB notification rate (a), TB incidence (b), TB
prevalence (c) and MTB infection rate (d) against time in years for the two cases considered
here. The results show that superinfection has a greater impact on tuberculosis which
increases with time. Comparing the results of the two-strain TB model with and without
superinfection, we find that there is an increase of 12.5%, 31.3%. 43.8% and 50% in 10, 20,
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FIG. 3.5. The impact of superinfection on tuberculosis. The graph of TB notification rate
(a), TB incidence rate (b), TB prevalence (c) and MTB infection rate (d) of system (3.1)
and (3.22). Parameter values are given in Table 3.3.
50 and 100 years respectively in the TB prevalence. An increase of 16.5%, 31.6%, 39.2%
and 42.7% in 10, 20, 50 and 100 years respectively in the TB incidence was also noted. Fig.
3.6 shows the percentage of active cases that arise due to superinfection. It was found that
0.46%, 0.94%, 2.1% and 3.0% of the active cases are due to superinfection in 10, 20, 50 and
100 years respectively. Fig. 3.7 shows the effect of strain coexistence. It was also established
that resistant strains were unable to emerge in the absence of superinfection. Progression to
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FIG. 3.6. The proportion of active cases due to superinfection. Parameter values are given
in Table 3.3.
active TB of strain 2 only or either strains after superinfection leads to strain coexistence.
A similar result was obtained in [39] where coexistence of strains was found to be possible
after putting superinfection by resistant strains into consideration. Castillo-Chavez and
 0
 5
 10
 15
 20
 25
 0  50  100  150  200
T
ot
al
 n
um
be
r 
of
 in
di
vi
du
al
s 
w
ith
 a
ct
iv
e 
T
B
Time (years)
strain 1
strain 2
(a)
 0
 5
 10
 15
 20
 25
 0  50  100  150  200
T
ot
al
 n
um
be
r 
of
 in
di
vi
du
al
s 
w
ith
 a
ct
iv
e 
T
B
Time (years)
strain 1
strain 2
(b)
FIG. 3.7. Coexistence of strains. The effect of strain coexistence in the absence (a), and
presence (b) of superinfection of the two-strain TB model. Parameter values are given in
Table 3.3.
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Feng [7] also found that strain coexistence was promoted by drug-resistance after adding
superinfection in their model. They also found that strain coexistence was possible without
superinfection if the resistant strains are due to antibiotic resistance (acquired resistance).
TABLE. 3.4. The characteristics of the endemic steady state of the one-strain TB model
and two-strain TB model.
One-strain TB model Two-strain TB model
Strain 1 Strain 2 No super- With super-
infection infection
Total population P 9,805 9,923 9,823 9,727
Susceptible S 5,388 8,406 4,593 3,880
Latent TB E1 4,406 - 5,214 4,539
E2 - 1,512 0 1,028
E12 - - - 257
Active TB I1 11 - 15 17
I2 - 5 0 7
TB notification rate (per 100,000/yr) 85 33 116 178
MTB prevalence 45.0% 15.3% 53.0% 60.0%
TB prevalence 0.11% 0.047% 0.16% 0.24%
MTB infection rate (per year) 0.017 0.0038 0.024 0.032
TB incidence rate (per 100,000/yr) 138 42 171 244
“Syblo’s ratio” 81 109 73 77
Reactivation 9.8% 11.0% 9.3% 24.3%
Reinfection 15.3% 3.8% 20.0% 15.2%
Superinfection - - - 3.7%
Primary progression 74.9% 85.2% 70.7% 56.8%
3.5 TB control measures
The fight against TB has been prevention of TB reactivation by the use of isoniazid pre-
ventive therapy (IPT) and treatment of the identified (detected) active TB cases. We
endeavour to study the effectiveness of the control measures and how they can change the
course of tuberculosis in the presence of superinfection. We are also interested in the extent
to which the control measures should be applied if we are to eliminate the epidemic. We
apply the control measures on the two-strain TB model with superinfection only which is
given by system (3.1).
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3.5.1 Isoniazid preventive therapy (IPT)
Isoniazid preventive therapy is a widely used control measure for preventing individuals
with latent TB from progressing to active TB. This control measure reduces the reactivation
rate of both strains if applied. In our model, the reactivation rate is taken to be the same
for both strains. Applying this control measure will decrease the reactivation rate of both
strains at the same rate. Fig. 3.8 shows the effect of a sudden decrease in the reactivation
rate of both strains. The results show that decreasing the reactivation rate of all individuals
latently infected with TB by 50% and 75% leads a 29.2% and 50% reduction in the TB
prevalence respectively in 10 years. Continuing with the intervention leads to a 34.8% and
56.2% reduction in the TB prevalence if the reactivation rate is decreased by 50% and 75%
respectively in 20 years.
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FIG. 3.8. Isoniazid preventive therapy. Assumption: treatment starting 15 years after the
introduction of drug-resistant TB. The graph of TB prevalence against time. The param-
eter a1 is replaced by a1, a1/2, a1/4, a1/8, 0, the parameter a2 by a2, a2/2, a2/4, a2/8, 0, the
parameter σ1 by σ1, σ1/2, σ1/4, σ1/8, 0 and the parameter σ2 by σ2, σ2/2, σ2/4, σ2/8, 0 from
top to bottom. Parameter values are given in Table 3.3.
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3.5.2 Increased TB detection
The recovery rates b1 and b2 for strain 1 and strain 2 are given as functions of their
respective detection rates γ1 and γ2 (that is, b1 = β1 + γ1ε1 and b1 = β1 + γ1ε1). Thus,
increased TB detection increases the recovery rates b1 and b2 for strain 1 and strain 2
respectively. Fig. 3.9 shows the effect of a sudden increase in the TB detection rate. We
are considering two cases. The first case looks at the sudden increase in the detection rate
of resistant strains keeping that of sensitive strains constant (Fig. 3.9 (a)). The results
of this case show that there is no change in the TB incidence as the detection rate of
resistant strains is increased. This is due to the fact that the incidence of resistant strains
is significantly lower than that of sensitive strains. The second case looks at a sudden
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FIG. 3.9. Increased TB detection. Assumption: treatment starting 15 years after the
introduction of drug-resistant TB. The graph of TB incidence against time for two cases
(increased detection rate for resistant strain only (a) and both strains (b)). The detection
parameter γ2 is replaced by γ2, 2γ2, 4γ2, 8γ2 from top to bottom (a), and the parameters
γ1 and γ2 by γ1, 2γ1, 4γ1, 8γ1 and γ2, 2γ2, 4γ2, 8γ2 respectively from top to bottom (b).
Parameter values are given in Table 3.3.
increase in the detection rate of both strains (Fig. 3.9 (b)). The results show that there is
a higher decrease in the TB incidence rate as the detection rate increases. Increasing the
detection rate of all individuals infected with active TB by 50% and 75% leads to 68.0%
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and 81.2% reduction in the TB incidence respectively in 10 years. A remarkable decrease
in the TB incidence is obtained when the detection rate of both strains is increased by 75%
or more. Thus, a balanced intervation for both strains is required if one is to eliminate the
TB epidemic.
3.6 Summary
In this chapter we studied qualitatively and quantitatively a six-dimensional deterministic
model for the transmission dynamics of tuberculosis by considering two strains of MTB
(that is, drug-sensitive and drug-resistant strains). The model was formulated to evaluate
the impact of superinfection on the tuberculosis epidemic. We first analysed the model with
only one strain (one-strain TB model) and one endemic equilibrium point was obtained
whenever RTB1 > 1. By using the center manifold theorem, it was found that the unique
endemic equilibrium point is locally asymptotically stable for RTB1 near 1. It was also
established that whenever RTB1 ≤ 1, the disease-free equilibrium point is globally asymp-
totically stable and unstable otherwise. These results have serious implications towards
the elimination of the disease.
The basic reproduction number, RTB0 of the two-strain TB model without superinfection
was obtained and the disease-free equilibrium point was established to be locally asymptot-
ically stable whenever RTB0 is less than 1 and unstable otherwise. The basic reproduction
numbers of the two-strain TB model with superinfection were obtained by first assuming
that most individuals progress to either strain 1 only or strain 2 only after superinfec-
tion. Two reproduction numbers were obtained for each case in the first analysis. We
later obtained a third reproduction number by assuming that individuals can progress to
either strain after superinfection depending on the fitness of the strain. We found that
the three reproduction numbers increase with an increase in the proportion of individuals
that progress to active TB of any strain after superinfection. We also noted that if most
individuals progress to active tuberculosis of strain 1, then the epidemic may grow faster
than when most individuals progress to active TB of strain 2 after superinfection. This
was due to the fact that the transmission rate of sensitive strains was taken to be higher
than that of resistant strains. Considering progression to active TB of strain 2 or either
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strain after superinfection was found to lead to strain coexistence.
Numerical simulations of the model were carried out to evaluate the impact of superinfec-
tion on the transmission of tuberculosis. We established that the impact of superinfection
on tuberculosis is high as the TB notification rate and TB incidence increased by about
51.7% and 42.7% respectively in 100 years. It was estimated that 3.0% of active cases were
due to superinfection in 100 years.
The impact of Increased TB detection and Isoniazid preventive therapy (IPT) on the
epidemic was studied. We observed that increasing the detection rate of both strains could
change the course of tuberculosis and hence eliminate the epidemic if high detection rates
of both strains are achieved. IPT reduces the TB prevalence but its impact on TB largely
depends on the rate at which latently infected individuals can be identified for treatment
since they do not show symptoms.
Chapter 4
HIV-TB coinfection model
4.1 Introduction
In this chapter, we extend the model given in chapter 3 to include HIV. The model still
comprises of two strains of TB (drug-sensitive and drug-resistant TB) and also incorporates
in superinfection of tuberculosis. We focus on the evaluation of the impact of superinfection
on both the prevalence of TB and HIV in a setting where the prevalence of HIV and TB
are already known to be high, as the case in sub-Saharan Africa. We will also focus on
the control measures and evaluate the effect of superinfection on these control measures.
We are also interested in knowing which of the control measures is most effective in the
presence of superinfection. Note that we are considering TB superinfection and not HIV
superinfection. A case where both TB superinfection and HIV superinfection are considered
is left for future research.
4.2 Model development
The model consists of twelve compartments, six for HIV-negative and the other six for
HIV-positive individuals. The negative superscript refers to HIV-negative individuals and
the positive superscript refers to HIV-positive individuals. All the variables and parameters
written with a negative superscript have the same meaning as those used in the two-strain
TB model in chapter 3. Again, the subscripts 1 and 2 refer to the sensitive and resistant
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strains respectively. The transmission dynamics of TB are exactly the same as the ones
discussed in the previous chapter. We assume that an individual can be infected with HIV
irrespective of one’s tuberculosis status. To reduce on the number of compartments we do
not distinguish the routes of HIV transmission like sexual transmission, blood transfusion
and mother to child transmission. We do not consider sex and age at which an individual
gets the infection into consideration. We also do not consider the stages of HIV. The
transmission rate for HIV is taken to be proportional to the prevalence of individuals with
HIV. We take a reduced transmission rate which is given by g(H), where
g(H) = de−λH , (4.1)
d is the maximum HIV transmission rate, λ is the parameter representing behaviour change
(through counselling, awareness programmes and others) and H is the HIV prevalence.
The term, e−λH is meant to reduce the transmission rate as people get to know the dan-
gers of contracting HIV and decide to change their sexual behaviour. The reduced HIV
transmission rate function, g(H) can also be interpreted in this way; when H is small,
the transmission rate is high as the number of susceptible individuals will be high and
as H increases, the transmission rate goes down because infectives run out of potential
susceptibles. Generally, g(H) is a decreasing function of H as shown in Fig. 4.1.
 0
 0.1
 0.2
 0.3
 0.4
 0.5
 0.6
 0.7
 0  0.05  0.1  0.15  0.2  0.25  0.3
g(H
)
HIV prevalence (H)
FIG. 4.1. The relationship between the reduced transmission rate, g(H) and HIV preva-
lence, H .
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The nonlinear function g(H) has already been used by Bacae˝r et al. [34] and Williams et
al. [5]. Fig. 4.2 gives a schematic representation of the HIV-TB coinfection model and
Table. 4.1 gives the similarity between the medical vocabulary and the model.
The model for the transmission of HIV and TB is given by the following system of differ-
ential equations:
dS−
dt
=B − S−(i1 + i2)− µ
−S− − g(H)HS−,
dE−1
dt
=[(1− p−)S− − q−
1
E−
1
]i1 − (a
−
1
+ µ− + c−i2)E
−
1
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1
)b−
1
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− g(H)HE−
1
,
dE−2
dt
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−
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−
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− + c−i1)E
−
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−
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−
2 I
−
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−
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−
1 i1 + ω
−
2 i2 + σ
−
1 + σ
−
2 + µ
−)E−12
+ τ−1 b
−
1 I
−
1 + τ
−
2 b
−
2 I
−
2 − g(H)HE
−
12,
dI−1
dt
=(p−S− + q−1 E
−
1 + θ
−
1 c
−E−2 + ω
−
1 E
−
12)i1 + a
−
1 E
−
1 + σ
−
1 E
−
12 − (b
−
1 + m
−)I−1 − g(H)HI
−
1 ,
dI−2
dt
=(p−S− + q−2 E
−
2 + θ
−
2 c
−E−1 + ω
−
2 E
−
12)i2 + a
−
2 E
−
2 + σ
−
2 E
−
12 − (b
−
2 + m
−)I−2 − g(H)HI
−
2 ,
dS+
dt
=− S+(i1 + i2)− µ
+S+ + g(H)HS−,
dE+
1
dt
=[(1− p+)S+ − q+1 E
+
1 ]i1 − (a
+
1 + µ
+ + c+i2)E
+
1 + (1− τ
+
1 )b
+
1 I
+
1 + g(H)HE
−
1 ,
dE+2
dt
=[(1− p+)S+ − q+
2
E+
2
]i2 − (a
+
2
+ µ+ + c+i1)E
+
2
+ (1− τ+
2
)b+
2
I+
2
+ g(H)HE−
2
,
dE+12
dt
=(1− θ+1 )c
+E+2 i1 + (1 − θ
+
2 )c
+)E+1 i2 − (ω
+
1 i1 + ω
+
2 i2 + σ
+
1 + σ
+
2 + µ
+)E+12
+ τ+1 b
+
1 I
+
1 + τ
+
2 b
+
2 I
+
2 + g(H)HE
−
12,
dI+
1
dt
=(p+S+ + q+1 E
+
1 + θ
+
1 c
+E+2 + ω
+
1 E
+
12)i1 + a
+
1 E
+
1 + σ
+
1 E
+
12 − (b
+
1 + m
+)I+1 + g(H)HI
−
1 ,
dI+2
dt
=(p+S+ + q+
2
E+
2
+ θ+
2
c+E+
1
+ ω+
2
E+
12
)i2 + a
+
2
E+
2
+ σ+
2
E+
12
− (b+
2
+ m+)I+
2
+ g(H)HI−
2
,


(4.2)
where i1 = (k
−
1 I
−
1 + k
+
1 I
+
1 )/P1 and i2 = (k
−
2 I
−
2 + k
+
2 I
+
2 )/P1 are the MTB infection rates for
strain 1 and 2 respectively. P1 is the total population which is given by
P1 = S
− + E−1 + E
−
2 + E
−
12 + I
−
1 + I
−
2 + S
+ + E+1 + E
+
2 + E
+
12 + I
+
1 + I
+
2
and H is the HIV prevalence which is also given by
H = (S+ + E+1 + E
+
2 + E
+
12 + I
+
1 + I
+
2 )/P1.
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All the parameters and variables are taken to be positive and the model lies within the
feasible region
W2 =
{
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−
2 , E
−
12, I
−
1 , I
−
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+, E+1 , E
+
2 , E
+
12, I
+
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2 ) ∈ R
12
+ : P1 ≤
B
µ
}
which is positively invariant with respect to system (4.2).
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FIG. 4.2. A schematic diagram showing the overall structure and the flows between the
different states of the HIV-TB coinfection model.
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TABLE. 4.1. Similarity between the medical vocabulary and the HIV-TB coinfection
model. Adopted from [34].
Total population P1 = S
−+E−1 +E
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−
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+
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−
1 + I
−
2 ) + k
+
2 (I
+
1 + I
+
2 )
}
/P1
TB cases T = a−1 E
−
1 +a
−
2 E
−
2 +a
+
1 E
+
1 +a
+
2 E
+
2 +(σ
−
1 +σ
−
2 )E
−
12+(σ
+
1 +σ
+
2 )E
+
12+
{(p−S−+q−1 E
−
1 +θ
−
1 c
−E−2 +ω
−
1 E
−
12)(k
−
1 I
−
1 +k
+
1 I
+
1 )+(p
−S−+q−2 E
−
2 +
θ−2 c
−E−1 + ω
−
2 E
−
12)(k
−
2 I
−
2 + k
+
2 I
+
2 ) + (p
+S+ + q+1 E
+
1 + θ
+
1 c
+E+2 +
ω+1 E
+
12)(k
−
1 I
−
1 +k
+
1 I
+
1 )+(p
+S++ q+2 E
+
2 + θ
+
2 c
+E+1 +ω
+
2 E
+
12)(k
−
2 I
−
2 +
k+2 I
+
2 )}/P1
TB incidence rate T/P1
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4.3 Mathematical analysis
The mathematical analysis of the TB-only model was discussed in chapter 3 section 3.3.
In this section we give the mathematical analysis of the HIV-only model. The analysis of
the HIV-TB model is done using numerical simulations.
4.3.1 Analysis of the HIV-only model
The model with HIV-only (obtained by setting
E−1 = E
−
2 = E
−
12 = I
−
1 = I
−
2 = E
+
1 = E
+
2 = E
+
12 = I
+
1 = I
+
2 = 0
in system (4.2)) is given by
dS−
dt
= B − µ−S− − g(H)HS−,
dS+
dt
= −µ+S+ + g(H)HS−,

 (4.3)
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where the HIV prevalence H is now given by H =
S+
(S− + S+)
. The total population is
also given by P2 = S
−+S+. The above system of equations given in (4.3) are the same as
the ones considered by Bacae˝r et al. [34] for HIV only.
The disease-free equilibrium of system (4.3) is given by X2 = (S0, 0) = (
B
µ−
, 0). Linearising
the second equation of (4.3) near the disease-free equilibrium S− = S0 and S
+ = 0 gives
dS+
dt
= −µ+S+ + g(H)
S+S0
(S0 + S+)
,
≃ −µ+S+ + g(0)S+,
= (g(0)− µ+)S+
From the above, its clear that the basic reproduction number for the HIV-only model is
given by
RHIV0 =
g(0)
µ+
.
This number is given by the product of the transmission coefficient g(0), at the disease
free-equilibrium and the average residence time 1
µ+
in the infectious class of an HIV infected
individual.
Since, g(H) = de−λH , it implies that g(0) = d. Therefore,
RHIV0 =
d
µ+
, (4.4)
and thus we have the following result.
Theorem 4.3.1 If RHIV0 < 1, the disease-free equilibrium point X2 is locally asymptoti-
cally stable and unstable if RHIV0 > 1.
The endemic steady states of the HIV-only model
Let the endemic steady state be given by ε∗ = (S−∗, S+∗), with H∗ =
S+∗
(S−∗ + S+∗)
. We
solve for the endemic equilibrium points by setting the right-hand sides of system (4.3) to
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zero and the system takes the form
B − µ−S−∗ − g(H∗)H∗S−∗ = 0, (4.5)
−µ+S+∗ + g(H∗)H∗S−∗ = 0. (4.6)
From H∗ = S+∗/(S−∗ + S+∗), we have
H∗S−∗ +H∗S+∗ = S+∗,
⇒ S−∗ =
(1−H∗)
H∗
S+∗.
Substituting for S−∗ in equation (4.6), we have
−µ+S+∗ + g(H∗)H∗
(1−H∗)
H∗
S+∗ = 0,
−S+∗[µ+ − g(H∗)(1−H∗)] = 0.
This equation has solutions, S+∗ = 0 and µ+ − g(H)(1 − H) = 0. The case S+∗ = 0
corresponds to the disease-free equilibrium X2.
Thus,
µ+ = g(H∗)(1−H∗), (4.7)
or
g(H∗) =
µ+
(1−H∗)
. (4.8)
Solving equation (4.5) for S−∗, we get
S−∗ =
B
µ− + g(H∗)H∗
,
=
B
µ− + µ
+
(1−H∗)
H∗
,
=
B(1−H∗)
µ−(1−H∗) + µ+H∗
.
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Also, solving equation (4.6) for S+∗, we get
S+∗ =
g(H∗)H∗S−∗
µ+
,
=
µ+
(1−H∗)
H∗B(1−H∗)
(µ−(1−H∗)+µ+H∗)
µ+
,
=
BH∗
µ−(1−H∗) + µ+H∗
.
Thus, the endemic steady states for the HIV-only model are given by
S−∗ =
B(1−H∗)
µ−(1−H∗) + µ+H∗
(4.9)
and
S+∗ =
BH∗
µ−(1−H∗) + µ+H∗
. (4.10)
We thus have the following Theorem on the existence of the endemic steady states.
Theorem 4.3.2 The endemic steady state ε∗ exists for 0 6 H∗ 6 1. If H∗ = 0, then the
endemic state collapses to the disease-free equilibrium. If H∗ = 1, then S−∗ = 0, implying
that everybody is infected.
4.4 Numerical Simulations
4.4.1 Parameter estimation
The estimation of all the TB related parameters was discussed fully in chapter 3 section
3.4.1 and we use the same parameter values for HIV-negative individuals. In this section we
give a discussion of how the HIV-TB related parameters were estimated. These parameters
were all estimated from the literature.
HIV parameters
The mortality for HIV-positive individuals was taken to be 0.1/yr which corresponds to
an average survival time of ten years. Williams et al. [5] assumed a median survival time
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of 9.8 years, Gross et al. [24] assumed an average survival time of 7.5 years in their HIV-1
superinfection and viral diversity model. This mortality was also taken to be 0.1/yr in [34]
(citing [48]), 0.13/yr in [13] (citing [3]), 0.15/yr in [22].
The function g(H) for the HIV infection rate was used by Bacae˝r et al. [34] and fitted
to data from a South African township and they obtained parameter values for d and λ
as 0.7/yr and 5.9/yr respectively. We also use these values in our model. With these
parameter values, the HIV transmission rate varies from 0.7/yr to 0.002/yr for H=0 to
H=1 respectively. Cohen et al. [48] took the HIV transmission rate to be 0.4/yr.
HIV-TB coinfection parameters
Infection and mortality parameters. The MTB infection rate was also taken to be the
product of active TB prevalence and the transmission rate as was done in the first model
in chapter 3. The MTB transmission rate was also taken to be 2
3
k1 and
2
3
k2 for strain 1
and strain 2 respectively as in [34] (citing [48]). The values of k1 and k2 are given in Table.
3.3, and denoted by k−1 and k
−
2 respectively in this chapter.
The TB mortality was assumed to be 1.6/yr for HIV-positive individuals as in [34] (citing
[15]). This value was taken to be 0.325/yr in [13] (citing [3] and other references), 1.0/yr
in [48].
Progression parameters. It was assumed that 67% of HIV-positive individuals progress
fast within a year to active tuberculosis after primary infection in [48]. Fast progression
to active tuberculosis in HIV-positive individuals was taken to be 20% per year in [13],
30% in [34] (by fitting data from a township in South Africa). We assume that 20% of the
HIV-positive individuals progress to active TB soon after primary infection as in [13].
Of those who are HIV-positive and latently infected with tuberculosis, it was assumed that
8% progress to active disease within a year through reactivation in [34] (citing [25] and
other references). It was assumed that 17% progress to active disease through reactivation
within a year but 30% have infectious TB in [22, 48]. The reactivation rate was also
assumed to be 0.737% per year in [13] (taken as an estimate for WHO, 1994). We consider
this value to be 8% per year as in [34].
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Primary infection is assumed to induce some protection towards any other incoming in-
fection [11, 34]. This protection was assumed to be 75% in [11] for both HIV-negative
and HIV-positive individuals, 25% in [34] (citing [48]) for HIV-positive individuals. We
take this value to be 75% as in [11]. We are thus taking the reinfection and superinfection
rates to be 0.25p+, where p+ is the probability of an HIV-positive individual progressing
to active TB after primary infection. Note that a protection of 25% is generally small.
Treatment-related parameters. The detection rate was taken to be 3.0/yr in [34]
(citing [40]) for drug-sensitive TB, 0.5/yr in [12], 0.5/yr in [48] for both drug-sensitive
and drug-resistant TB, 0.7/yr in [8] for drug-resistant TB. This value was taken to be 4.0
per person per year in [22] (citing [8] and other references) for both smear-positive and
smear-negative tuberculosis. We take this value to be 3.0/yr as in [34] for drug-sensitive
TB and 0.7/yr as in [8] for drug-resistant TB.
The rate of self-cure was taken to be 0.4/yr as in [34] (citing [15]) for both strains. This
value was taken to be 0.1/yr in [48], 0.7/yr in [12].
Successful treatment of detected cases was taken to be 73% as in [48] (taken as a policy)
for drug-sensitive TB and 30% as in [48] for drug-resistant tuberculosis. This value was
taken to be 80% in [34] (citing [40]), 70% in [12] for drug-sensitive tuberculosis.
With these values of our choice, we get b+1 ≃ 2.8/yr and b
+
2 ≃ 1.3/yr as successful recovery
rates for drug-sensitive and drug-resistant TB respectively. Comparing these values with
what others have, we find that Guwatudde et al. [13] used a cure rate of 0.5/yr for drug-
sensitive TB, Sharomi et al. [36] used a treatment rate to lies in the range 0.5-5 per year
for drug-sensitive TB.
The respective tuberculosis detection probabilities are given by
γ−1 + γ
−
2
γ−1 + γ
−
2 + β
−
1 + β
−
2 +m
−
≃ 67% and
γ+1 + γ
+
2
γ+1 + γ
+
2 + β
+
1 + β
+
2 +m
+
≃ 61%
for HIV-negative and HIV-positive individuals. In terms of strains the respective proba-
bilities of detection for HIV-positive individuals are
γ+1
γ+1 + β
+
1 +m
+
≃ 60% and
γ+2
γ+2 + β
+
2 +m
+
≃ 26%
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for strain 1 and strain 2. The respective average durations of the disease are also given by
1
b+1 +m
+
≃ 0.2 year and
1
b+2 +m
+
≃ 0.4 year
for strain 1 and 2 in HIV-positive individuals, giving a difference of 2 months. This implies
that in HIV-positive individuals, the period of infectiousness of a resistant TB case is on
average 2 months longer than that of a sensitive TB case.
4.4.2 Simulations of the HIV-only model
This subsection presents the solutions of the HIV-only model given in system (4.3). Pa-
rameter values in Table. 4.2 were used. The reproduction number was determined to
be
RHIV0 ≃ 7.0.
We then assumed that H∗ = 1 and solved equations (4.5) and (4.6) to obtain the initial
condition for susceptible and infected individuals. Fig. 4.3 gives the plots of the individual
population size of susceptible and infected classes, and the HIV prevalence of the HIV-only
model.
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FIG. 4.3. The individual population size of susceptibles and infected (a), and the HIV
prevalence (b) of the HIV-only model. Parameter values are given in Table 4.2.
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TABLE. 4.2. The parameter values for the HIV-TB coinfection.
Parameter definition Value Reference
HIV transmission rate d 0.7/yr [34] (fit)
Mortality µ+ 0.1/yr [34, 48]
HIV prevention λ 5.9 [34] (fit)
TB mortality m+ 1.6/yr [34] (citing [15])
MTB transmission rate k+1 , k
+
2
2
3
k1,
2
3
k2 [34] (citing [48])
TB infection -fast progression p+ 20% [13]
TB reactivation a+1 , a
+
2 0.08/yr [34] (citing [25])
σ+1 , σ
+
2 0.08/yr [34]
TB reinfection q+1 , q
+
2 0.25p
+ [11, 39]
ω+1 , ω
+
2 0.25p
+ [11, 39]
TB superinfection c+ 0.25p+ [11, 39]
Recovery without treatment β+1 , β
+
2 0.4/yr [34] (citing [15])
Detection rate γ+1 , γ
+
2 3.0/yr , 0.7/yr [34] (citing [40]),[8]
Treatment ε+1 , ε
+
2 73% , 30% [48]
A proportion of individuals that are latently
infected with TB of strain 2 who progress
to active TB of strain 1 after being super-
infected with TB of strain 1
θ+1 75% Estimated
Proportion of individuals that are latently
infected with TB of strain 1 who progress
to active TB of strain 2 after being super-
infected with TB of strain 2
θ+2 75% Estimated
Proportion of individuals that are actively
infected with TB of strain 1 and latently
infected with TB of strain 2 that enter state
E+12 after treatment
τ+1 50% Estimated
Proportion of individuals that are actively
infected with TB of strain 2 and latently
infected with TB of strain 1 that enter state
E+12 after treatment
τ+2 50% Estimated
4.4.3 Simulations of the HIV-TB coinfection model
In this subsection we present the numerical results from the simulations of system (4.2).
The parameter values were picked from both Table. 3.3 and Table. 4.2 for TB alone and
HIV-TB coinfection respectively. The steady state values of the two-strain TB model given
in Table. 3.4 were used as the initial conditions. We assume that HIV was introduced in
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the population in the year 1984 with TB at a steady state by that year. We also introduce
one HIV infected individual in the model who is assumed to be in the S+ class.
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FIG. 4.4. The impact of TB superinfection on tuberculosis in HIV-TB coinfected individ-
uals. The graph of TB notification rate (a), TB incidence rate (b), TB prevalence (c) and
MTB infection rate (d) of system (4.2). Parameter values are given in Table 4.2.
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4.4.4 The impact of HIV on tuberculosis
The model shows that there is a greater increase in the number of TB cases due to HIV. Fig.
4.4 shows the simulation curves of TB notification rate, TB incidence rate, TB prevalence
and MTB infection rate. A greater increase in these rates is attributed to the presence of
HIV. Without considering TB superinfection, the TB notification rate was observed to be
1,519 cases per 100,000 persons per year. With TB superinfection, the TB notification rate
increases to 1,454 cases per 100,000 persons per year. The steady state value of the HIV
prevalence was estimated to be 24.5% in the absence of TB superinfection and 23.5% in the
presence of TB superinfection (Table. 4.3). A study on the trends of the TB notification
rate was done in a South African Peri-Urban Community where the HIV prevalence was
estimated to be as high as 22% by Lawn et al. [45]. Without considering TB superinfection,
the TB notification rate was found to be about 1,500 cases per 100,000 persons per year.
4.4.5 The impact of TB superinfection on tuberculosis in HIV
infected individuals
The impact of TB superinfection on tuberculosis in HIV-TB coinfected individuals is rel-
atively low compared to that in HIV negative individuals. Comparing the results of the
HIV-TB coinfection model with and without TB superinfection, we find that there is an
increase of 55%, 8.8%, 5.3% and 4.6% in the TB incidence in 10, 20, 50 and 100 years re-
spectively. An increase of 45%, 20%, 27% and 23% in the TB prevalence in 10, 20, 50 and
100 years respectively was also observed. The early increase in the incidence and prevalence
of TB is due to the fact that the model is coming from a TB steady state where it was
shown that the impact of TB superinfection on TB is very high (chapter 3). These results
show that the impact of TB superinfection in HIV-TB coinfected individuals reduces with
time. The relatively low impact of TB superinfection on TB is attributed to HIV whose
effect on TB is known to be high. The impact of TB superinfection in a HIV-positive
population is shown in Fig. 4.4. Fig. 4.5 (a) shows the percentage of active cases that
are caused by TB superinfection. There is a drop from the initial value of 3.7% obtained
from the TB steady state in chapter 3 to around 2.1% in 100 years. The two strains of
TB were found to coexist only in the presence of TB superinfection (Fig. 4.6). The same
result was obtained in chapter 3 in the two-strain TB model without HIV. It was observed
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FIG. 4.5. Proportion of active cases caused by TB superinfection (a) and the HIV preva-
lence of the HIV-TB coinfection model. Parameter values are given in Table 4.2.
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FIG. 4.6. Coexistence of strains. The effect of strain coexistence in the absence (a), and
presence (b) of TB superinfection of the HIV-TB coinfection model. Parameter values are
given in Table 4.2.
that TB superinfection leads to a decrease in the prevalence of HIV, though by a small
percentage. Much as it is believed that tuberculosis does not cause any impact on HIV
prevalence, TB superinfection affects the prevalence of HIV. This result is due to the fact
that tuberculosis accelerates the progression of HIV to AIDS and increases the associated
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HIV mortality. Thus, TB superinfection in HIV infected individuals causes more death
leading to a decrease in the prevalence of HIV. This result is shown in Fig. 4.5 (b).
TABLE. 4.3. The characteristics of the endemic steady state of the HIV-only model and
HIV-TB coinfection model.
HIV-TB coinfection model
HIV-only No TB super- With TB super-
model infection infection
Total population P 4,760 4,293 4,181
Susceptible S− 3,450 1,229 1,194
S+ 1,310 246 238
Latent TB E−1 - 1,995 1,493
E−2 - 0 384
E−12 - - 105
E+1 - 787 511
E+2 - 0 122
E+12 - - 92
Active TB I−1 - 18 15
I−2 - 0 6
I+1 - 17 13
I+2 - 0 9
TB notification rate (per 100,000/yr) - 1,519 1,454
MTB prevalence - 65.6% 65.8%
TB prevalence - 0.82% 1.0%
HIV prevalence 27.5% 24.5% 23.5%
MTB infection rate (per year) - 0.10% 0.11%
TB incidence rate (per 100,000/yr) - 2,145 2,246
“Syblo’s ratio” - 210 211
Reactivation - 69.0% 70.4%
Reinfection - 10.5% 7.2%
Superinfection - - 2.1%
Primary progression - 20.5% 20.3%
4.5 HIV and TB control measures
We now evaluate possible control measures firstly by looking at the control measures on
HIV in the form of condom use and antiretroviral therapy (ART). Secondly we look at
the control measures for TB in the form of isoniazid preventive therapy and increased TB
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detection. We start by considering condom use.
4.5.1 Condom use
An increase in condom use reduces the sexual contact rate and thus reducing the HIV
transmission rate d. We evaluated the impact of increased condom use by lowering the
value of d. Fig. 4.7 (a) shows the graph of the TB notification rate and Fig. 4.7 (b) shows
the graph of the HIV prevalence obtained for different values of d. From these graphs
its clear that a decrease in the value of d leads to a decrease in the TB notification rate
and HIV prevalence. A decrease in the maximum transmission rate d of 50% leads to a
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FIG. 4.7. Increasing condom use. Assumption: increase starting in 2009. Simulation
curves showing the effect of increased condom use on the TB notification rate (a) and HIV
prevalence (b). The parameter d is replaced by d, d/2, d/4, d/8, 0 from to bottom in both
cases. Parameter values are given in Table 4.2.
16.0% and 20.8% reduction in the TB notification rate and HIV prevalence respectively in
5 years. Decreasing the value of d by 75% leads to a 25.8% and 34.1% reduction in the TB
notification rate and HIV prevalence respectively in 5 years. 87.5% reduction in the value
d takes the notification rate close to the original value obtained at the TB steady state in
about 80 years and reduces the HIV prevalence to less than one in 45 years.
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4.5.2 Antiretroviral therapy (ART)
Antiretroviral therapy (ART) is one of the major control measures used to lower the HIV
viral load and prevent the progression of HIV to AIDS in the world today. If initiated,
this control measure is believed to increase the life expectancy of HIV infected individuals
by at least 20 years [34]. Since ART lowers the viral load, there is a reduction in the
transmission of HIV. ART also reduces the MTB reactivation rate of individuals who are
latently infected with TB. Fig. 4.8 shows the graphs of the TB notification rate and HIV
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FIG. 4.8. ART. Assuming that all HIV-positive individuals are put on ART by 2009. The
graph of TB notification rate (a) and HIV prevalence (b) obtained after the initiation of
ART. The parameters µ+, m+, a+1 , a
+
2 , σ
+
1 and σ
+
2 are replaced by µ
+/2, m+/2, a+1 /4,
a+2 /4, σ
+
1 /4 and σ
+
2 /4 respectively. From top to bottom d is replaced by d, d/2, d/4, d/8, 0.
The red curve shows the case without intervation. Parameter values are given in Table 4.2.
prevalence that were obtained after including all the assumptions that would occur if ART
is initiated. The life expectancy was taken to be 20 years giving a value of µ+ = 0.05 per
year as in [34]. The other parameters were taken to be a+1 = a
+
2 = σ
+
1 = σ
+
2 = 0.08/4 = 0.02
per year and m+ =1.6/2 = 0.8 per year. The results show that decreasing the maximum
transmission rate d by 50% with the above assumptions leads to a 60.0% reduction in the
TB notification rate in 5 years. Decreasing d by 75% leads to a 62.8% reduction in the
TB notification rate in 5 years. The HIV prevalence decreases when the transmission rate
d is reduced by 50% or more. A decrease of 50% and 75% in d leads to a 12.9% and 20%
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reduction in the HIV prevalence respectively in 5 years.
4.5.3 Isoniazid preventive therapy (IPT)
Isoniazid preventive therapy (IPT) is used for treating latent tuberculosis. It reduces the
reactivation rate of individuals that are latently infected with TB. Fig. 4.9 shows the
graphs of the TB prevalence obtained after the initiation of Isoniazid preventive therapy
on HIV-positive individuals. There is a significant reduction in the TB prevalence as the
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FIG. 4.9. The impact of Isoniazid preventive therapy on HIV-TB coinfected indi-
viduals assuming that treatment starts in 2009. The parameter a+1 is replaced by
a+1 , a
+
1 /2, a
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1 /4, a
+
1 /8, 0, the parameter a
+
2 by a
+
2 , a
+
2 /2, a
+
2 /4, a
+
2 /8, 0, the parameter σ
+
1
by σ+1 , σ
+
1 /2, σ
+
1 /4, σ
+
1 /8, 0 and the parameter σ
+
2 by σ
+
2 , σ
+
2 /2, σ
+
2 /4, σ
+
2 /8, 0 from top to
bottom. Parameter values are given in Table 4.2.
reactivation rate decreases. Decreasing the reactivation rate of all HIV-positive individuals
latently infected with TB by 50% and 75% leads to a 40.4% and 62.6% reduction in the TB
prevalence respectively in 5 years. 87.5% decrease in the reactivation rate of HIV-positive
individuals takes the TB prevalence close to the one obtained at the TB steady state in
about 10 years.
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4.5.4 TB detection
Recovery from active TB was considered to be through self cure and successful treatment
of detected cases. This implies that increased TB detection increases the recovery rate
from active TB for both HIV-negative and positive individuals. Fig. 4.10 (a) shows the
effect of increased TB detection rate in HIV-positive individuals and Fig. 4.10 (b) shows
the effect of increased TB detection rate in all TB infected individuals regardless of their
HIV status. The two graphs show that the incidence rate decreases with an increase in
 0
 500
 1000
 1500
 2000
 2500
 1980  2000  2020  2040  2060  2080
Time (years)
TB incidence (per 100,000 per year)
(a)
 0
 500
 1000
 1500
 2000
 2500
 1980  2000  2020  2040  2060  2080
Time (years)
TB incidence (per 100,000 per year)
(b)
FIG. 4.10. TB detection. Assuming that there is an increase in TB detection rate starting
in 2009. TB incidence rate obtained due to an increase in TB detection for HIV-positive in-
dividuals only (a), all TB infected individuals (b). The parameters γ+1 and γ
+
2 are replaced
by γ+1 , 2γ
+
1 , 4γ
+
1 , 8γ
+
1 and γ
+
2 , 2γ
+
2 , 4γ
+
2 , 8γ
+
2 respectively from top to bottom for case (a).
The parameter γ−1 is replaced by γ
−
1 , 2γ
−
1 , 4γ
−
1 , 8γ
−
1 , the parameter γ
−
2 by γ
−
2 , 2γ
−
2 , 4γ
−
2 , 8γ
−
2 ,
the parameter γ+1 by γ
+
1 , 2γ
+
1 , 4γ
+
1 , 8γ
+
1 and the parameter γ
+
2 by γ
+
2 , 2γ
+
2 , 4γ
+
2 , 8γ
+
2 from
top to bottom for case (b). Parameter values are given in Table 4.2.
the detection rate. Increasing the TB detection rate of HIV-negative individuals by 50%
and 75% leads to a 4.6% and 8.8% reduction in the TB incidence respectively in 5 years.
Increasing the TB detection rate of both HIV-negative and HIV-positive individuals by
50% and 75% leads to a 11.8% and 18.3% reduction in the TB incidence respectly in
5 years. The increase in detection rate of all TB infected individuals looks to be more
appropriate than increasing the detection rate of HIV-positive individuals only since the
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effect in the latter is significantly small.
4.6 Summary
This chapter gives a mathematical model used to describe the interaction between HIV
and TB epidemics. The model consists of two strains of M. tuberculosis and includes in
the possibility of TB superinfection. The analysis of the HIV-only model shows that the
disease-free equilibrium is locally asymptotically stable whenever the reproduction number
is less than one and unstable otherwise.
Numerical simulations were carried out and it was established that HIV drives the TB epi-
demic with the TB notification rate increasing to almost 1,519 cases per 100,000 persons
per year in the absence of TB superinfection, and almost 1,454 cases per 100,000 persons
per year in the presence of TB superinfection. Approximately 2.0% of the active cases were
found to be due to TB superinfection. The HIV prevalence was estimated to be approx-
imately 24.5% and 23.5% in the absence and presence of TB superinfection respectively.
It was also found that TB superinfection leads to strain coexistence, a similar result that
was obtained in chapter 3.
Analysis of the control measures show that condom use, isoniazid preventive therapy (IPT)
and antiretroviral therapy (ART) have a positive impact in controlling tuberculosis. Con-
dom use largely decreases the HIV prevalence compared to antiretroviral therapy (ART).
Increased TB detection rate is less effective in controllong TB in HIV-TB coinfected indi-
viduals.
Chapter 5
Conclusions
In this thesis we developed a mathematical model for the dynamics of HIV-TB coinfection
with a view of gaining a better understanding of the impact of TB superinfection on
the prevalence and incidence of tuberculosis in both HIV-negative and HIV-TB coinfected
individuals. This is the first attempt to use a mathematical model to do such an evaluation.
Chapter 3 of this project concentrated on the analysis of TB superinfection in HIV-negative
individuals only. We demonstrated that the impact of superinfection on tuberculosis can
not be ruled out as other modellers have been doing since it increases the prevalence and
incidence tuberculosis.
By considering sensitive tuberculosis alone (one-strain TB model), it was established that
most of the active cases arise from primary progression (about 75%), but as drug-resistance
comes in (two-strain TB model), active cases due to primary progression goes down (about
71%) and become even smaller when superinfection is put into consideration (about 57%).
Due to TB superinfection, a great number of active cases through reactivation (about 24%)
were observed.
In the two-strain TB model, it was observed that resistant strains can not compete in the
absence of TB superinfection. Coexistence of sensitive and resistant strains was shown to
happen in the presence of TB superinfection only. This result do not differ significantly
from the one obtained by Rodrigues et al. [39] and Castillo-Chavez et al. [7] in which
they found that superinfection promotes strain coexistence. The same result was obtained
after introducing HIV in the model. The dependency of the basic reproduction number
76
Chapter 5. Conclusions 77
of the two-strain TB model with superinfection on some key parameters was analytically
and numerically investigated. It was established that progression to active TB of the drug-
sensitive strain would accelerate the TB epidemic at a higher rate compared to progression
to active TB of the drug-resistant strain after superinfection if the transmission rate of the
sensitive strains is higher than that of the resistant strains. However, if the transmission
rate of resistant strains is higher than that of sensitive strains, then progression to active
TB of the resistant strain after superinfection accelerates the epidemic at a much higher
rate than progression to active TB of the sensitive strain after superinfection.
Chapter 4 concentrated on the analysis of TB superinfection in HIV-TB coinfected indi-
viduals. The impact of TB superinfection in HIV-TB coinfected individuals was found
to be relatively smaller than the one in HIV-negative individuals. The impact of HIV on
tuberculosis was shown to be high, with the TB prevalence rising to 0.82% and 1.0% in
absence and presence of TB superinfection. The TB incidence was found to increase to
2,145 and 2,246 per 100,000 per year in the absence and presence of TB superinfection.
Due to this high impact, it was found that the effect of TB superinfection on the prevalence
and incidence of TB in HIV-TB coinfected individuals is less.
Although increased TB detection rate led to a high decrease in the number of TB cases in
HIV-negative individuals, it was noticed that the effect of increasing TB detection rate in
HIV-TB coinfected individuals does not give a clear result. Increased TB detection rate
and Isoniazid preventive therapy (IPT) looks to be more appropriate in changing the course
of the TB epidemic in HIV-negative and HIV-positive individuals respectively. This result
looks to be different from what Bacae˝r et al. [34] obtained in their model where increased
TB detection in HIV-positive individuals was shown to decrease the TB incidence. This
could be due to drug-resistance and TB superinfection which is considered in our model.
It was also established that increased condom use has a greater impact on HIV prevalence
and TB notification rate. Antiretroviral therapy (ART) was also found to decrease the TB
notification rate and its impact on HIV prevalence requires high coverage. A similar result
was obtained by Bacae˝r et al. [34].
Although the model was developed in accordance with previous models in the literature,
there is also need to evaluate the model using experimental data. This would help in
getting good estimates for the parameters used most especially the reactivation rate of
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individuals latently infected with two strains, the proportion of individuals who progress
to active TB soon after superinfection and the proportion of individuals that progress to
active tuberculosis of each strain after superinfection.
As a future perspective, it would be important to know the impact of HIV superinfection
and viral diversity on the prevalence and incidence of tuberculosis. To reduce on the
number of compartments and parameters, we considered TB superinfection only. A case
with both TB and HIV superinfection would also give interesting results.
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